

**CIAN HEALTHCARE LIMITED**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308**  
**CIN: L24233PN2003PLC017563**

**STATEMENT OF STANDALONE PROFIT AND LOSS FOR THE PERIOD ENDING ON MARCH 31, 2024**

Particulars	Note No.	For the year ended March 31, 2024	For the year ended March 31, 2023
		Rs. (in Lakhs)	Rs. (in Lakhs)
<b>A CONTINUING OPERATIONS</b>			
1 Income from operations	22	5,874.89	6,756.13
2 Other income	23	106.08	53.81
3 <b>Total Income (1+2)</b>		<b>5,980.97</b>	<b>6,809.94</b>
4 <b>Expenses</b>			
(a) Cost of materials consumed	24.a	4,148.38	3,569.05
(b) Purchases of stock-in-trade	24.b	319.51	1,011.44
(c) Changes in inventories of finished goods, work-in-progress	24.c	-1,065.09	-484.86
(d) Other Operating Expenses	25	416.42	405.67
(d) Employee benefits expense	26	759.60	805.91
(e) Finance costs	27	472.76	418.45
(f) Depreciation and amortisation expense	12.A & 12.B	368.19	364.42
(g) Other expenses	28	560.14	603.14
<b>Total expenses</b>		<b>5,979.91</b>	<b>6,693.22</b>
5 <b>Profit / (Loss) before exceptional and extraordinary items and tax (3 - 4)</b>		<b>1.06</b>	<b>116.72</b>
6 Exceptional items	29.a		
7 <b>Profit / (Loss) before extraordinary items and tax (5 ± 6)</b>		<b>1.06</b>	<b>116.72</b>
8 Extraordinary items	29.b	-0.20	-3.32
9 <b>Profit / (Loss) before tax (7 ± 8)</b>		<b>1.26</b>	<b>120.04</b>
10 <b>Tax expense:</b>			
(a) Current tax expense for current year - MAT		0.20	20.04
(b) (Less): MAT credit (where applicable)			
(c) Current tax expense relating to prior years		-18.93	-
(d) Net current tax expense		-18.73	20.04
(e) Deferred tax		-18.97	-7.68
		-37.70	12.36
11 <b>Profit / (Loss) from continuing operations (9 ± 10)</b>		<b>38.96</b>	<b>107.68</b>
12 <b>Earnings per share (24995764 Shares of Rs. 10/- each):</b>			
(a) Basic			
(i) Continuing operations		0.16	0.43
(ii) Total operations		0.16	0.43
(b) Diluted			
(i) Continuing operations		0.16	0.43
(ii) Total operations		0.16	0.43

As per our attached Report of even date

For Agarwal Mahesh K & Co.  
Chartered Accountant  
FRN: 008007C

CA Ashish Boudhik  
Partner  
M No. 156089  
UDIN: 24156089BKR0511554  
PLACE: PUNE  
DATE: 30.05.2024



For and on behalf of  
CIAN HEALTHCARE LIMITED

Mr. Sunil Zanwar  
Managing Director  
DIN: 01304850  
Munaji Dhuma  
Company Secretary  
M NO. A65852  
Date: 30.05.2024

Mr. Paresh Shah  
Director  
DIN: 08502901  
Mr. Riyaz Khan  
CFO  
DIN: 07578366  
Place: Pune



**CIAN HEALTHCARE LIMITED**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308**  
**CIN: L24233PN2003PLC017563**

**STATEMENT OF STANDALONE BALANCE SHEET AS AT MARCH 31, 2024**

Particulars		Note No.	(Rs. In Lakhs)	(Rs. In Lakhs)
			As at Mar 31, 2024	As at March 31, 2023
<b>A</b>	<b>EQUITY AND LIABILITIES</b>			
1	Shareholders' funds			
	(a) Share capital	3	2,499.58	2,499.58
	(b) Reserves and surplus	4	3,681.57	3,642.61
	(c) Money received against share warrants			
2	Share application money pending allotment			
3	Non-current liabilities			
	(a) Long-term borrowings	5	1,528.61	1,289.93
	(b) Deferred tax liabilities (net)	30.11	91.21	110.17
	(c) Other long-term liabilities	6	770.31	631.17
	(d) Long-term provisions	7	101.97	90.63
4	Current liabilities			
	(a) Short-term borrowings	8	2,572.27	2,981.34
	(b) Trade payables	9		
	(a) Total outstanding dues of micro enterprises and small enterprises		569.05	723.68
	(b) Total outstanding dues of creditors other than micro enterprises and small enterprises		1,944.93	1,638.99
	(c) Other current liabilities	10	470.42	401.45
	(d) Short-term provisions	11	59.28	53.72
	<b>TOTAL</b>		<b>14,289.21</b>	<b>14,063.28</b>
<b>B</b>	<b>ASSETS</b>			
1	Non-current assets			
	(a) Property, Plant and equipment & Intangible Assets			
	(i) Tangible Assets	12.A	2,588.38	2,941.85
	(ii) Capital work-in-progress	12.B	1,469.93	1,388.60
	(iii) Intangible assets under development			
	(iv) Fixed assets held for sale			
	(b) Non-current investments	13	708.84	708.84
	(c) Deferred tax assets (net)	30.11		
	(d) Long-term loans and advances	14	1,116.66	1,081.53
	(e) Other non-current assets	15	1,929.32	1,118.47
2	Current assets			
	(a) Current investments	16	-	-
	(b) Inventories	17	3,767.88	3,480.99
	(c) Trade receivables	18	1,830.41	2,353.92
	(d) Cash and cash equivalents	19	72.74	112.57
	(e) Short-term loans and advances	20	449.13	442.26
	(f) Other current assets	21	355.93	434.24
	<b>TOTAL</b>		<b>14,289.21</b>	<b>14,063.28</b>

As per our attached Report of even date  
For Agarwal Mahesh K & Co.  
Chartered Accountant  
FRN: 008007C

CA Ashish Boundia  
Partner  
M No. 156089  
UDIN: 24156089BKBVMTT12  
PLACE: PUNE  
DATE: 30.05.2024



For and on behalf of  
**CIAN HEALTHCARE LIMITED**

Mr. Sunil Zanwar  
Managing Director  
DIN: 01304850

Mr. Rishabh Dhuma  
Company Secretary  
M NO. A65852

Mr. Paresh Shah  
Director  
DIN: 08502901

Mr. Riyaz Khan  
CFO  
DIN: 07578366



Date: 30.05.2024  
Place: Pune

**CIAN HEALTHCARE LIMITED**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308**  
**CIN: L24233PN2003PLC017563**

**STATEMENT OF STANDALONE CASHFLOW AS AT MARCH 31, 2024**

Particulars	As at Mar 31, 2024	As at March 31, 2023
<b>Cash Flow from operating activities</b>		
Net Profit after tax	38.96	107.68
Adjustment for:		
- Depreciation and amortization expense	368.19	364.42
- Depreciation reserve written off	-	-
- (Profit) / Loss on Sale/Disposal of assets	-	-
- Interest Expenses	435.82	408.08
- Interest & Dividend received	-3.42	-4.56
- Deferred Tax Liability	-18.97	-7.68
<b>Operating profit before working capital changes</b>	<b>820.58</b>	<b>867.95</b>
(Increase) / Decrease in Other Non Current asset	-810.85	-720.55
(Increase) / Decrease in Inventories	-286.89	-79.30
(Increase) / Decrease in Trade receivables	523.52	-527.87
(Increase) / Decrease in Other Current Assets	78.32	643.14
(Increase) / Decrease in Deferred Tax Asset	-	-
(Increase) / Decrease in other financial assets	-6.87	9.64
Increase / (Decrease) in Provisions	16.89	28.97
Increase / (Decrease) in Trade Payables	151.32	-516.63
Increase / (Decrease) in Other Financial Liabilities/Short Term Borrowing	-	-
Increase / (Decrease) in Deferred tax liabilities	-	-
Increase / (Decrease) in Other Current Liabilities	68.98	-64.03
Increase / (Decrease) in Other Non Current Liabilities	139.14	573.87
<b>Cash generated from operations</b>	<b>694.13</b>	<b>215.18</b>
Taxes paid	-	-
<b>Net cash from operating activities</b>	<b>694.13</b>	<b>215.18</b>
<b>Cash flow from Investing activities</b>		
Purchase of fixed assets	-14.77	-24.19
Proceeds from sale of fixed assets/Subsidy	0.06	-
(Increase) / Decrease in Capital Work in Progress	-81.32	-88.75
Interest & Dividend received	3.42	4.56
Purchases of Shares of Dr. Smiths Biotech Private Ltd.	-	-
Proceeds / (Repayment) of Other Financial Assets/Long Term Liabilities	-	-
<b>Net Cash flow from investing activities</b>	<b>-92.62</b>	<b>-108.38</b>
<b>Cash flow from financing activities</b>		
Proceeds from issuance of Share Capital including share premium	-	-
Proceeds from long term borrowings	238.67	-709.31
Proceeds / (Repayment) from / of short term borrowings (Above)	-409.07	672.13
Proceeds from Share Application Money	-	-
Dividend Paid including dividend distribution tax	-	-
Proceeds / (Repayment) for Other Financial Assets	-35.13	328.76
Interest paid	-435.82	-408.08
<b>Net Cash flow from Financing Activities</b>	<b>-641.34</b>	<b>-116.50</b>
<b>Increase / (Decrease) in cash and cash equivalents</b>	<b>-39.83</b>	<b>-9.70</b>
Cash and cash equivalents at beginning of the year	112.57	122.27
<b>Cash and cash equivalents at end of the year</b>	<b>72.74</b>	<b>112.57</b>

**Notes :**

- i) The above Cash flow statement has been prepared under the indirect method set out in Accounting Standard-3, "Cash Flow Statement" notified under section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules 2014.
- ii) Details of Cash and cash equivalents are given in note No.2.04 and 2.05
- iii) Direct Tax paid is treated as arising from operating activities and are not bifurcated between investment and financing activities.
- iv) All figures in brackets/Negative indicate outflow.

As per our attached Report of even date  
For Aggarwal Mahesh & Co.  
Chartered Accountants  
FRN:008007C

CA Ashish Boudia  
Partner  
M.No - 156089  
PLACE: PUNE  
Place : Pune  
Date : 30/05/2024



For and on behalf of Board of Directors  
Cian Healthcare Limited  
CIN:L24233PN2003PLC017563

Mr. Munjaji Dhmal  
Company Secretary  
M No. A65852  
Place : Pune  
Date : 30/05/2024

Mr. Sunil Zanwar  
Managing Director  
DIN: 01304850  
Place : Pune  
Date : 30/05/2024

Mr. Paresh Shah  
Director  
DIN: 07984882  
Place : Pune  
Date : 30/05/2024


Mr. Riyaz Khan  
CFO  
DIN: 07578366  
Place : Pune  
Date : 30/05/2024



**Notes:**

1. The Above Financial Results and Statement of Assets and Liabilities were prepared as per Accounting Standards and reviewed by the audit committee and then approved by the Board of Directors at their respective meetings held on 30th May, 2024
2. The Results for the half year ended on March 31, 2024 are audited by the Statutory Auditors of the company in compliance with the regulation 33 of SEBI (LODR) Regulations, 2015
3. The Earning Per Share (EPS) has been computed in accordance with the AS-20
4. List of Subsidiary as on March 31, 2024  
Name of the Entity : Dr. Smiths Biotech Private Limited  
Relationship : Subsidiary  
Country of Incorporation : India  
% of Ownership : 100%
5. Other Income for the half year ended on March 31, 2024 includes Interest on Fixed Deposits, Income from Export benefits & Other Misc. Income and Realized and Unrealized Foreign Exchange Gain/ (Loss)
6. The Status of Investors Complaints during the half year ended on March 31, 2024 is as under  
Pending at the beginning of the above period: NIL  
Received during the above period: NIL  
Disposed during the above period: NIL  
Remaining unsolved at the end of the above period: NIL
7. Figures of previous year/Period have been regrouped/recasted wherever necessary, in order to make them comparable.
8. The company is primarily engaged in the business of Pharmaceuticals which is single reportable segment for the half year/ year ended March 31, 2024 hence no separate segment reporting is given as per AS-17.
9. As per MCA Notification dated 16.02.2015, companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital disclosure Requirements) Regulations, 2009 are Exempted from the compulsory requirement of Adoption of IND-AS. Hence company has prepared its financials as per Accounting Standards

**For and on behalf of Board of Directors**  
**CIAN HEALTHCARE LIMITED**  
**CIN:L24233PN2003PLC017563**

  
**Mr. Sunil Zanwar**  
**Managing Director**  
**DIR: 01304850**



**Notes:**

1. The Above Financial Results and Statement of Assets and Liabilities were prepared as per Accounting Standards and reviewed by the audit committee and then approved by the Board of Directors at their respective meetings held on **30th May, 2024**
2. The Results for the half year ended on 31st March,2024 are audited by the Statutory Auditors of the company in compliance with the regulation 33 of SEBI (LODR) Regulations,2015
3. The Earning Per Share (EPS) has been computed in accordance with the AS-20
4. The consolidated accounts have been prepared as per AS-21
5. List of Subsidiary as on 31st March 2024  
Name of the Entity : Dr. Smiths Biotech Private Limited  
Relationship : Subsidiary  
Country of Incorporation : India  
% of Ownership : 100%
6. Other Income for the year ended on 31.03.2024 includes Interest on Fixed Deposites, Income from Export benefits & Other Misc. Income
7. The Status of Investors Complaints during the year ended on 31.03.2024 is as under  
Pending at the beginning of the above period: NIL  
Received during the above period: NIL  
Disposed during the above period: NIL  
Remaining unsolved at the end of the above period: NIL
8. Figures of previous year/Period have been regrouped/recasted wherever necessary, in order to make them comparable.
9. The company is primarily engaged in the business of Pharmaceuticals which is single reportable segment for the half year/ year ended 31.03.2024 hence no separate separate segment reporting is given as per AS-17



**CIAN HEALTHCARE LIMITED**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308**  
**CIN: L24233PN2003PLC017563**

**Ratios Analysis**  
**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE PERIOD ENDING ON MARCH 31, 2024**

Sr. No.	Particulars	Current Year 2023-24	Previous Year 2022-23
1	Debt Equity Ratio	0.25	0.21
2	Debt Service Coverage Ratio	3.23	3.40
3	Interest Service Coverage Ratio	4.96	5.66

Sr. No.	Particulars	Current Year 2023-24	Previous Year 2022-23	Variance	Comments For Variations in Ration
1	Current Ratio	1.15	1.18	-2.27%	No major variance
2	Debt Equity Ratio	0.14	0.18	-20.88%	Due to Repayment of Outsiders Long term loan
3	Debtors T/o	2.81	0.81	246.67%	Due to Increase in collection of Debtor
4	Stock T/o	234.74	188.58	24.48%	Due to Increase in turnover
5	Creditors T/o	2.94	3.53	-16.85%	No major variance
6	Working Capital	860.13	1,024.81	-16.07%	Due to Increase in collection of Debtor
7	GP Ratio	42.08%	39.38%	6.86%	Due to Increase in COGS
8	NP Ratio	0.02%	1.78%	-98.80%	Increase in admin cost, profit reduced
9	Cash Profit	369.44	484.46	-23.74%	Increase in admin cost, profit reduced
10	Cash NP Ratio	6.29%	7.17%	-12.30%	Increase in admin cost, profit reduced
11	ROI	0.02%	1.62%	-98.99%	Increase in admin cost, profit reduced
12	ROE	0.02%	1.95%	-98.96%	Increase in admin cost, profit reduced
13	EPS (FV Rs.10/-)	0.16	0.43	63.82%	Increase in admin cost, profit reduced
14	Interest Coverage Ratio	1.85	2.19	-15.52%	Due to Decrease in Net Profit



**CIAN HEALTHCARE LIMITED**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308**  
**CIN: L24233PN2003PLC017563**

**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE PERIOD ENDING ON MARCH 31, 2024**

**Note 1: Corporate Information**

CIAN HEALTHCARE LIMITED("the Company") is a public limited company and was incorporated and domiciled in India having its registered office at MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT,Maharashtra, India. The Company is engaged in the Manufacturing and marketing of pharmaceutical products.

The Corporate Office of the Company is situated at : 508-511, Sacred World, 5th Floor, Above Macdonald, Vitthal Rao Shivarkar Road, Wanowrie, Pune - 411040.

The Company has its manufacturing plant situated at Khasara No.248,Village Sisona,P.O.Bhagwanpur, Roorkee-247 667,Dist : Haridwar ( Uttarakhand)

**Note 2: Significant Accounting Policies**

**2.01 Basis of accounting and Preparation of Accounting Statements**

**A) Compliance with Accounting Standards**

The Financial Statements of the company have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) The company has prepared these financial statements to comply in all material respects with the accounting standards notified under section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules 2014. The financial statements have been prepared on an accrual basis and under the historical cost convention. The financials are prepared according to Indian Accounting Standards (AS)

**B) Current and Non-current classification**

The assets and liabilities reported in the balance sheet are classified on a "current/noncurrent basis", with separate reporting of assets held for sale and corresponding liabilities. Current assets, which include cash and cash equivalents are assets that are intended to be realized, sold or consumed during the normal operating cycle of the Company. Based on the nature of products and the time between the acquisition of assets for processing and their realisation in cash and cash equivalents, the company has ascertained its operating cycle as 12 months for the purpose of current/non-current classification of assets

**2.02 Use of estimates**

The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of revenues and expenses during the year and balances of assets, liabilities and the disclosure of contingent liabilities on the date of the financial statements. Actual results could differ from those estimates. Any revision to accounting estimates is recognized

**2.03 Inventories**

Inventories of Raw Material, Packing Material and Stock-in-Trade are valued at the lower of cost and the net realisable value after providing for obsolescence and other losses, where considered necessary. Cost includes all charges in bringing the goods to the point of sale, including octroi and other levies, transit insurance and receiving charges excluding GST. The costs are valued at Weighted Average cost Formula.

Work in Progress are valued at the cost of Conversion of inventories, includes cost directly related to the units of production, such as direct labour. There is stage wise systematic allocation of fixed and variable production overheads that are incurred.

Finished Goods are valued at net realizable value or cost whichever is lower. Valuation of Cost of finished good includes all the conversion costs directly attributable to product and other Administrative overheads.

The inventories have been certified by the management for both physical verification and valuation.

The inventories are kept at the below mentioned locations by the company for the Closing stock As at Mar 31, 2024

**1. Registered office situated at**

**Address:** Milkat No.3339, Block No.1 From South Side, C.S.No.227/2+3A,Harpale Park,Opp.Berger Paint, Phursungi, Tal. Haveli,Dist. Pune-412308, Maharashtra

**2. Plant/Factory situated at**

**Address:** Khasara No.248,Village Sisona,P.O.Bhagwanpur, Roorkee-247 667,Dist : Haridwar, Uttarakhand

**2.04 Cash and Cash Equivalent**

Cash and cash equivalents comprises cash on hand and at banks, short-term deposits (with an original maturity of three months or less from the date of acquisition), and which are subject to insignificant risk of changes in value.

For the purpose of statement of cash flows, cash and cash equivalents consist of cash and short term deposits, as defined above, net of outstanding book overdrafts , if any, as they are considered an integral part of the company's cash management.

**2.05 Cash flow statement**

Cash flows are reported using the indirect method, whereby profit / (loss) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated based on the available information.



CIAN HEALTHCARE LIMITED  
MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,  
C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT  
PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308  
CIN: L24233PN2003PLC017563

**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE PERIOD ENDING ON MARCH 31, 2024**

**2.06 Depreciation**

Depreciation has been provided on the straight-line method as per the prescribed in Schedule II of the Companies Act, 2013 and assets are amortised as

Land	0 Years
Building	30 Years
Computers	3 Years
Furniture	10 Years
Office Equipment	5 Years
Plant & Machinery	10 Years
Vehicles	8 Year

Depreciation on additions/ disposals of the fixed assets during the year is provided on pro-rata basis according to the period during which assets were put

Intangible assets are amortised over their estimated useful life of 5 years as per the management decision.

Asset block of Intangible assets has the carrying value of zero for year 19-20, 20-21, 21-22, 22-23 and 23-24. Also there is no addition in the block of assets during the year.

The estimated useful life of the intangible assets and the amortisation period are reviewed at the end of each financial year and the amortisation method is revised to reflect the changed pattern.

**2.07 Revenue recognition**

- a) Revenue is measured at the fair value of the consideration received or receivable. Amounts disclosed as revenue are exclusive of Goods and Service Tax and net of discounts, applicable taxes and returns. The company recognises revenue when the amount of revenue can be reliably measured, when it is probable that future economic benefits will flow to the entity and when specific criteria have been met for each of the company's activities, as described
- b) Provision for sales returns are estimated on the basis of historical experience, market conditions and specific contractual terms and provided for in the year of sale as reduction from revenue. The methodology and assumptions used to estimate returns are monitored and adjusted regularly in line with contractual and legal obligations, trade practices, historical trends, past experience and projected market conditions.
- c) Other income:
  - i) Dividend income is recognized when the right to receive dividend is established.
  - ii) Interest income is recognized using the time-proportion method, based on rates implicit in the transaction.
  - iii) Other income is recognised when no significant uncertainty as to its determination or realisation exists.

**2.08 Fixed Assets**

**Tangible fixed assets**

Property, Plant and Equipment are stated at cost of acquisition/construction net of recoverable taxes less accumulated depreciation / amortization, government grants and impairment loss, if any. All costs attributable to acquisition of Property, Plant and Equipment till assets are put to use, are capitalized. Subsequent expenditure on Property, Plant and Equipment after its purchase / completion is capitalized only if such expenditure results in an increase in the future benefits from such asset beyond its previously assessed standard of performance.

**Capital work-in-progress:**

Projects under which assets are not ready for their intended use and other capital work-in-progress are carried at cost, comprising direct cost, related incidental expenses and attributable interest.

**Intangible Assets**

Intangible assets are carried at cost less accumulated amortisation and impairment losses, if any. The cost of an intangible asset comprises its purchase price, including any import duties and other taxes (other than those subsequently recoverable from the taxing authorities), and any directly attributable expenditure on making the asset ready for its intended use and net of any trade discounts and rebates. Subsequent expenditure on an intangible asset after its purchase / completion is recognised as an expense when incurred unless it is probable that such expenditure will enable the asset to generate future economic benefits in excess of its originally assessed standards of performance and such expenditure can be measured and attributed to the asset reliably.

**2.09 Foreign currency transactions and translations**

Initial recognition

Transactions in foreign currencies entered into by the Company and its integral foreign operations are accounted at the exchange rates prevailing on the date of the transaction or at rates that closely approximate the rate at the date of the transaction.

Measurement of foreign currency monetary items at the Balance Sheet date

Foreign currency monetary items (other than derivative contracts) of the Company and its net investment in non-integral foreign operations outstanding at the Balance Sheet date are restated at the year-end rates.

In the case of integral operations, assets and liabilities (other than non-monetary items), are translated at the exchange rate prevailing on the Balance Sheet date. Non-monetary items are carried at historical cost. Revenue and expenses are translated at the average exchange rates prevailing during the year. Exchange differences arising out of these translations are charged to the Statement of Profit and Loss.

Treatment of exchange differences

Exchange differences arising on settlement / restatement of short-term foreign currency monetary assets and liabilities of the Company and its integral foreign operations are recognised as income or expense in the Statement of Profit and Loss.





NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE PERIOD ENDING ON MARCH 31, 2024

**2.10 Government grants, subsidies and export incentives**

Government grants and subsidies are recognised when there is reasonable assurance that the Company will comply with the conditions attached to them and the grants / subsidy will be received. Government grants whose primary condition is that the Company should purchase, construct or otherwise acquire capital assets are presented by deducting them from the carrying value of the assets. The grant is recognised as income over the life of a

Export benefits are accounted for in the year of exports based on eligibility and when there is no uncertainty in receiving the same.

**2.11 Investments**

Long-term investments (excluding investment properties), are carried individually at cost less provision for diminution, other than temporary, in the value of such investments. Current investments are carried individually, at the lower of cost and fair value. Cost of investments include acquisition charges such

Investment properties are carried individually at cost less accumulated depreciation and impairment, if any. Investment properties are capitalised and depreciated (where applicable) in accordance with the policy stated for Tangible Fixed Assets. Impairment of investment property is determined in

Investment in Dr. Smiths Biotech Private Limited has been valued at cost as per AS-13

**2.12 Employee benefits**

**i) Short Term Employee Benefits**

Short term employee benefits are expensed as & when the related service is provided. A liability is recognized for the amount expected to be paid if the company has existing legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be

**ii) Long-Term Employee Benefits**

The liability for the earned leave is not expected to be settled wholly within twelve months after the end of the period in which the employees render the related service. They are therefore measured as the present value of expected future payments to be made in respect of services provided by employees upto the end of reporting period with actuarial valuations being carried out at each balance sheet date. The benefits are discounted using market yields at the end of the reporting period that have terms approximating to the terms of the related obligations.

**iii) Post Employment Benefits**

**a) Defined Contribution Plan**

Payments to defined contribution retirement benefit plans are recognised as expenses when the employees have rendered the service entitling themselves to the contribution.

Provident Fund: The employees of the company are entitled to receive the benefits in respect of provident fund, a defined contribution plan, in which both employees and the company make monthly contributions at a specific percentage of the covered employees salary. ( currently 12% of employee's salary) The contributions are made only for those employees whose salary is below or at par with the limit prescribed by the law. The contributions as specified under the law are made to the provident fund and pension fund administered by Regional Provident Fund Commissioner

The Company recognises the such contributions as and expenses when incurred.

**b) Defined Benefit Plans**

For defined benefit retirement plans, the cost of providing benefits is determined using the projected unit credit method, with actuarial valuations being carried out at the end of each annual reporting period. Re-measurements, comprising actuarial gains and losses, the effect of changes to asset ceiling (if applicable) and the return on plan assets (excluding net interest), is recognised in profit and loss account for the period in which they occur.

Defined benefit costs comprising service cost (including current and past service cost and gains and losses on curtailments and settlements) and net interest expenses or income is recognised in profit and loss.

The defined benefit obligation recognised in the balance sheet represents the actual deficit or surplus in the company's defined benefit plans. Any surplus resulting from this calculation is limited to the present value of any economic benefits available in the form of refunds from the plans or reductions in

The obligations are presented as a current liabilities in the balance sheet in the entity does not have an unconditional right to defer the settlement for at least twelve months after the reporting period, regardless of when actual settlement is expected to occur.

Gratuity: The company has an obligation towards gratuity, a defined benefit retirement plan covering eligible employees. The plan provides lump sum payments to vested employees at retirement, death while in employment or on termination of employment of an amount as per the provisions of the Payment of Gratuity Act,1972. Vesting occurs upon completion of five years of service. The company accounts for the liability for gratuity benefits payable in future based on an independent actuarial valuation carried out at each balance sheet date using projected credit method.

**2.13 Employee share based payments**

Company has not announced any employee stock option scheme during the year.



NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE PERIOD ENDING ON MARCH 31, 2024

**2.14 Borrowing costs**

Borrowing costs specifically relating to the acquisition, construction or production of qualifying assets that necessarily takes a substantial period of time to get ready for its intended use are capitalized ( net of income on temporarily deployment of funds) as part of the cost of such assets. Borrowing costs consist of Interest and other costs that the company incurs in connection with the borrowing of funds.

For general borrowing used for the purpose of obtaining a qualifying asset, the amount of borrowing costs eligible for the capitalization is determined by applying a capitalization rate to the expenditure on that assets. The capitalization rate is the weighted average of the borrowing costs applicable to the borrowings of the company that are outstanding during the period, other than borrowings made specifically for the purpose of obtaining a qualifying

All other borrowing costs are recognized in profit and loss in the period in which they are incurred.

The amount of borrowing costs capitalized during a period does not exceed the amount of borrowing costs incurred during that period.

**2.15 Earnings Per Share**

Basic earnings per share is computed by dividing the profit or loss attributable to equity shareholders of the Company by the weighted average number of equity shares outstanding during the year. Diluted earnings per share is the same as basic earnings per share as the company does not have any dilutive potential equity shares outstanding. The number of weighted equity shares are adjusted for share splits and bonus shares, as appropriate.

**2.16 Taxes on Income**

Current tax is the tax payable on the taxable profit for the year, using tax rates enacted or substantively enacted by the end of reporting period by the governing taxation laws, and any adjustment to tax payable in respect of previous periods. Income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

Deferred taxes arising from deductible and taxable temporary differences between the tax base of assets and liabilities and their carrying amount in the financial statements are recognized using substantively enacted tax rates and laws expected to apply to taxable income in the years in which the temporary differences are expected to be received or settled. Deferred tax asset are recognized only to the extent that it is probable that future taxable profit will be available against which the deductible temporary differences can be utilized. The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax assets to

**2.17 Leases:**

Lease arrangements where the risks and rewards incidental to ownership of an asset substantially vest with the lessor are recognised as operating leases. Operating lease payments are recognized as an expense on a straight line basis over the lease term unless the payments are structured to increase in line with the expected general inflation so as to compensate for the lessor's expected inflationary cost increases.

**2.18 Provisions, Contingent Liabilities and Contingent Assets**

**Provisions:**

Provisions are recognized only when there is a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate can be made.

**Contingent liability:**

- a) Possible obligations which will be confirmed only by future events not wholly within the control of the company, or
- b) Present obligations arising from past events where it is not probable that an outflow of resources will be required to settle the obligation or a reliable estimate of the amount of the obligation cannot be made.

**Contingent Assets**

A contingent asset is a possible asset that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company. Contingent assets are not recognised and disclosed only when an inflow of



CIAN HEALTHCARE LIMITED  
MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,  
C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT  
PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308  
CIN: L24233PN2003PLC017563

NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE PERIOD ENDING ON  
MARCH 31, 2024

Note 3: Share Capital

Particulars	As at Mar 31, 2024		As at March 31, 2023	
	Number of shares	Amount (Rs. In Lakhs)	Number of shares	Amount (Rs. In Lakhs)
(a) Authorised Equity shares of Rs. 10.00 each with voting rights	250,000,000.00	2,500.00	250,000,000.00	2,500.00
(b) Issued Equity shares of Rs. 10.00 each with voting rights	24,995,764.00	2,499.58	24,995,764.00	2,499.58
(c) Subscribed and fully paid up Equity shares of Rs. 10.00 each with voting rights	24,995,764.00	2,499.58	24,995,764.00	2,499.58
<b>Total</b>	<b>24,995,764.00</b>	<b>2,499.58</b>	<b>24,995,764.00</b>	<b>2,499.58</b>

Reconciliation of the number of shares and amount outstanding at the beginning and at the end of the reporting period:

Particulars	As at Mar 31, 2024		As at March 31, 2023	
	Number of shares	Amount (Rs. In Lakhs)	Number of shares	Amount (Rs. In Lakhs)
As at the beginning of the year	24,995,764.00	2,499.58	24,995,764.00	2,499.58
*****Add: Shares Allotted during the year	-	-	-	-
As at the end of the year	24,995,764.00	2,499.58	24,995,764.00	2,499.58

Shareholders holding more than 5% shares in the Company

Name of the Shareholder	As at Mar 31, 2024		As at March 31, 2023	
	Number of shares	% of Shareholding	Number of shares	% of Shareholding
Suraj Zanwar	2,521,847.00	10.09	5,759,847.00	23.04
Kavita Zanwar	302,000.00	1.21	2,400,000.00	9.60
Pankaj Zanwar	3,440,000.00	13.76	4,200,000.00	16.80
Prakash Chandra Rathi	3,853,153.00	15.42	4,999,153.00	20.00
<b>Total</b>	<b>10,117,000.00</b>	<b>40.47</b>	<b>17,359,000.00</b>	<b>69.45</b>



**CIAN HEALTHCARE LIMITED**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308**  
**CIN: L24233PN2003PLC017563**

**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE PERIOD ENDING ON MARCH 31, 2024**

**Note 4: Reserves and Surplus**

Particulars	(Rs. In Lakhs)	(Rs. In Lakhs)
	As at Mar 31, 2024	As at March 31, 2023
<b>Reserves and surplus</b>		
<b>(a) Securities premium account</b>		
Opening balance	3,581.11	3,581.11
Add : Premium on shares issued during the year	-	-
Less : Utilised during the year for:		
Issuing bonus shares		
Writing off preliminary expenses		
Writing off shares / debentures issue expenses		
Premium on redemption of redeemable preference shares / debentures		
Buy back of shares		
Closing balance	3,581.11	3,581.11
<b>(b) General reserve</b>		
Balance brought forward from last year	61.50	-46.18
Add: Profit/ (Loss) for the year	38.97	107.68
Add: Share Application money pending allotment		
Less: Bonus Issued from general Reserves		
Less: Other Net Adjustments made for previous years		
Add: Other Adjustments due to changes in Last period		
Closing balance	100.47	61.50
<b>(c) Depreciation Revaluation Reserve</b>	-	-
<b>Total</b>	<b>3,681.58</b>	<b>3,642.61</b>



**CIAN HEALTHCARE LIMITED**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308**  
**CIN: L24233PN2003PLC017563**

**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE PERIOD ENDING ON**  
**MARCH 31, 2024**

Note 5: Long Term Borrowings	(Rs. In Lakhs)	(Rs. In Lakhs)
Particulars	As at Mar 31, 2024	As at March 31, 2023
<u>Long Term Loans from Banks-Secured* (Refer Note 32 for the security details)</u>		
Term Loan - Idbi Bank A/C- 0338	-	1.56
Term Loan-SIDBI-D0000UGJ	65.51	153.14
Term Loan-SIDBI-D0000THM	22.14	56.85
Term Loan - BOB A/C - 197	39.17	40.18
Term Loan - BOB - 0183	669.16	684.40
Term Loan-BOB A/C-71010600000191	27.31	47.20
Term Loan - UBI A/C-7691	-	2.75
Term Loan - UBI A/C-7780	-	1.20
Term Loan - UBI A/C-8108	27.14	-
TERM LOAN - BOB - FITL A/C- 968	-	3.95
TERM LOAN - BOB - FITL A/C- 969	-	1.34
TERM LOAN - UBI - FITL A/C- 001	-	-
TERM LOAN - IDBI BANK FITL A/C- 2783	-	0.89
TERM LOAN - BOB - FITL A/C- 1240	-	31.72
TERM LOAN-SIDBI FITL-D0003QT7	1.46	2.46
TERM LOAN-SIDBI FITL-D0003QTC	2.95	4.20
<b>Total-Long Term Loans from Banks-Secured</b>	<b>854.84</b>	<b>1,031.83</b>
<u>Long Term Loans from Banks-Unsecured</u>		
Term Loan - HDFC Bank	1.85	14.22
Term Loan - Kotak Mahindra Bank	1.92	12.49
Term Loan - ECL Finance Ltd.	0.00	0.03
Term Loan - Tata Cap Fin Ser Ltd - 0424	-	0.02
Term Loan - Indusind Bank	-	-
Term Loan - Axis Bank	-	-
Term Loan - Fullerton	0.17	-
Term Loan - Magma Fincorp	0.96	-
Term Loan - Shriram City Finance	0.54	0.01
Term Loan - Standard Chartered	-	-
Term Loan - Deutsche Bank	0.00	9.00
Term Loan - Poonawalla Finance	-	0.00
Term Loan - Intellcash	-	-
Term Loan - Neo Growth	-	-
Term Loan - India Infoline Finance Ltd.	0.00	0.02
Term Loan - Intellcash - 131	0.00	-0.41
Term Loan-ECL Finance Ltd	0.36	2.98
<b>Total-Long Term Loans from Banks-Unsecured</b>	<b>5.82</b>	<b>38.34</b>
<u>Vehicle Loans- Secured against Hypothecation of Vehicle</u>		
Yes Bank Vehicle Loan( Secured against BMW Car)	8.15	18.95
Yes Bank Vehicle Loan( Secured against S Cross Car)	-	-
Yes Bank Vehicle Loan( Secured against Innova Car)	-	2.09
<b>Total- Vehicle Loans- Secured against Hypothecation of Vehicles</b>	<b>8.15</b>	<b>21.03</b>
<u>Loans &amp; Advances from Related Parties</u>		
Suraj Zanwar	659.81	198.72
<b>Total- Loans &amp; Advances from Related Parties</b>	<b>659.81</b>	<b>198.72</b>
<b>Total Long Term Borrowings</b>	<b>1,528.61</b>	<b>1,289.93</b>



**CIAN HEALTHCARE LIMITED**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308**  
**CIN: L24233PN2003PLC017563**

**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE PERIOD  
ENDING ON MARCH 31, 2024**

**Note 6: Other Long Term Liabilities**

Particulars	(Rs. In Lakhs)	(Rs. In Lakhs)
	As at Mar 31, 2024	As at March 31, 2023
(i) Payables on purchase of fixed assets		
(ii) Contractually reimbursable expenses		
(iii) Interest accrued but not due on borrowings		
(iv) Interest accrued on trade payables		
(v) Interest accrued on others		
(vi) Trade / security deposits received	770.31	631.17
(vii) Advances from customers		
(viii) Income received in advance (Unearned revenue)		
(ix) Others		
<b>Total</b>	<b>770.31</b>	<b>631.17</b>

**Note 7: Long Term Provision**

Particulars	As at Mar 31, 2024	As at March 31, 2023
<u>(a) Provision for employee benefits:</u>		
(i) Provision for compensated absences	12.52	9.69
(ii) Provision for gratuity (net)	87.85	80.94
(iii) Provision for post-employment medical benefits		
(iv) Provision for other defined benefit plans (net)		
(v) Provision for other employee benefits	1.60	-
<u>(b) Provision for Other:</u>		
<b>Total</b>	<b>101.97</b>	<b>90.63</b>



CIAN HEALTHCARE LIMITED  
MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,  
C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT  
PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308  
CIN: L24233PN2003PLC017563

NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE PERIOD ENDING ON MARCH 31, 2024

Note 8: Short Term Borrowings	(Rs. In Lakhs)	(Rs. In Lakhs)
Particulars	As at Mar 31, 2024	As at March 31, 2023
<b>A Current maturities of Long Term Borrowings</b>		
<u>Current Maturities of Long Term Borrowings-Secured* (Refer Note 32 for the security details)</u>		
IDBI Bank Term Loan	-	134.76
Term Loan-SIDBI-D0000UGJ	120.00	108.00
Term Loan-SIDBI-D0000THM	56.25	74.40
Term Loan - BOB A/C - 197	40.42	146.40
Term Loan - BOB - 0183	45.00	36.54
Term Loan-BOB A/C-71010600000191	27.24	22.80
Term Loan - UBI A/C-7691	-	57.20
Term Loan - UBI A/C-7780	0.86	35.97
Term Loan - UBI A/C-8108	32.16	73.67
TERM LOAN - BOB - FITL A/C- 968	5.34	4.92
TERM LOAN - BOB - FITL A/C- 969	1.78	1.68
TERM LOAN - UBI - FITL A/C- 001	-	4.88
TERM LOAN - IDBI BANK FITL A/C- 2783	2.47	7.92
TERM LOAN - BOB - FITL A/C- 1240	18.98	4.20
TERM LOAN-SIDBI FITL-D0003QT7	2.47	5.16
TERM LOAN-SIDBI FITL-D0003QTC	5.54	8.40
	<b>358.51</b>	<b>726.90</b>
<u>Current Maturities of Long Term Borrowings-Unsecured</u>		
Term Loan - HDFC Bank	12.81	9.24
Term Loan - Kotak Mahindra Bank	12.73	8.53
Term Loan - ECL Finance Ltd	0.65	11.24
Term Loan - Tata Cap Fin Ser Ltd - 0424	0.46	8.61
Term Loan - Fullerton	-	0.22
Term Loan - Magma Fincorp	-	11.97
Term Loan - Shriram City Finance	-	5.57
Term Loan - Deutsche Bank	10.49	9.60
Term Loan - Poonawalla Finance	0.79	5.31
Term Loan - India Infoline Finance Ltd.	0.01	9.93
Term Loan-ECL Finance Ltd	2.61	2.03
	<b>41.37</b>	<b>82.25</b>
<u>Current Maturities of Long Term Borrowings Vehicle Loans</u>		
Yes Bank Vehicle Loan( Secured against BMW Car)	11.06	9.09
Yes Bank Vehicle Loan( Secured against S Cross Car)	0.23	2.51
Yes Bank Vehicle Loan( Secured against Innova Car)	1.17	2.22
	<b>12.46</b>	<b>13.82</b>
(ii) Term Loan Interest accrued but not due	-	14.82
<b>B Loans Replayable on Demand</b>		
(i) From banks		
<b>Secured Loans</b>		
IDBI Bank Cash Credit	1,226.64	1,218.90
Bank of Baroda Cash Credit	347.95	338.23
UBI (C C ) - 560101000005431	578.03	566.77
<b>Unsecured Loans</b>		
Bajaj Fianace -402HFB84763337	7.30	19.67
<b>Total</b>	<b>2,572.27</b>	<b>2,981.34</b>



**CIAN HEALTHCARE LIMITED**  
MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,  
C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT  
PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308  
CIN: L24233PN2003PLC017563

NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE PERIOD  
ENDING ON MARCH 31, 2024

Particulars	(Rs. In Lakhs)	(Rs. In Lakhs)
	As at Mar 31, 2024	As at March 31, 2023
<b>Note 9: Trade Payable</b>		
Due to MSME creditors		
Due To Small & Micro	569.05	723.68
Due to Medium	325.91	90.69
Trade payables to related parties (Refer Sub note below)	-	-
Other Than Above Trade Payables- RM, PM, FG	768.53	1,190.07
<b>Total Trade Payables- RM, PM, FG</b>	<b>1,663.49</b>	<b>2,004.44</b>
Trade Payable- Expenses	850.50	358.22
(Refer note 29 i) for detailed Ageing of Trade Payables		
<b>Total Trade Payable</b>	<b>2,513.98</b>	<b>2,362.66</b>

Particulars	(Rs. In Lakhs)	(Rs. In Lakhs)
	As at Mar 31, 2024	As at March 31, 2023
<b>Note 10: Other Current Liabilities</b>		
(a) Other payables		
(i) Statutory remittances (Contributions to PF and ESIC, TDS.)	57.55	28.38
(ii) Payables on purchase of fixed assets	-	-
(iii) Salary and Remuneration Payable	90.40	68.10
(iv) Interest accrued on trade payables		
(v) Interest accrued on others		
(vi) Trade / security deposits received		
(vii) Advances From Debtors	322.48	304.97
(Refer note 29 i) for detailed Ageing of Advances from Debtors		
<b>Total</b>	<b>470.42</b>	<b>401.45</b>

Particulars	(Rs. In Lakhs)	(Rs. In Lakhs)
	As at Mar 31, 2024	As at March 31, 2023
<b>Note 11: Short-term provisions</b>		
(a) Provision for employee benefits: @		
(i) Provision for bonus		
(ii) Provision for compensated absences		
(iii) Provision for gratuity	6.04	8.43
(iv) Provision for post-employment medical benefits		
(v) Provision for other defined benefit plans (net) (give details)		
(vi) Provision for other employee benefits (give details)	10.75	9.76
(vii) Provision for other employee benefits (give detail)	1.31	
(b) Provision - Others:		
(i) Provision for Tax	20.23	20.04
(ii) Provision - others ( Expenses)	8.57	-
(iii) Provision - others	12.38	15.50
<b>Total</b>	<b>59.28</b>	<b>53.72</b>

Particulars	(Rs. In Lakhs)	(Rs. In Lakhs)
	As at Mar 31, 2024	As at March 31, 2023
<b>Sub Note</b>		
(i) Directors		
(ii) Other officers of the Company		
(iii) Firms in which any director is a partner		
Unilink Marketing Pvt Ltd	-	-
(iv) Private companies in which any director is a director or member		
Dr. Smiths Biotech Private Limited	-	-
<b>Total</b>	<b>-</b>	<b>-</b>





**CIAN HEALTHCARE LIMITED**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308**  
**CIN: L24233PN2003PLC017563**

NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE PERIOD ENDING ON MARCH 31, 2024

**Note:12A: Fixed Asset-Tangible Assets**

(Rs. In Lakhs)

Sr. No.	Particulars	Gross Block As at March 31, 2023	Additions	(Disposal)/Subsidy	Gross Block As at Mar 31, 2024	Depreciation				W.D.V. As at Mar 31, 2024	W.D.V. As at March 31, 2023
						As at March 31, 2023	For the period	On disposals	As at Mar 31, 2024		
1	Land	41.74			41.74	-	-		-	41.74	41.74
2	Building	2,231.67			2,231.67	345.56	74.39		419.95	1,811.71	1,886.10
3	Vehicle	113.04			113.04	76.18	11.62		87.80	25.24	36.86
4	Office Equipment	19.00	0.69		19.69	14.55	1.24		15.79	3.90	4.45
5	Computers	101.65	1.00		102.65	99.27	1.39		100.66	1.99	2.38
6	Plant & Machinery	2,106.92	13.07	0.06	2,119.94	1,163.70	264.35		1,428.04	691.89	943.22
7	Furniture	151.95			151.95	124.86	15.20		140.05	11.90	27.10
	<b>Total</b>	<b>4,765.96</b>	<b>14.77</b>	<b>0.06</b>	<b>4,780.68</b>	<b>1,824.11</b>	<b>368.19</b>	<b>-</b>	<b>2,192.30</b>	<b>2,588.38</b>	<b>2,941.85</b>

**Note:12A: Fixed Asset-Intangible Assets**

Sr. No.	Particulars	Gross Block As at March 31, 2023	Additions	(Disposal)/Subsidy	Gross Block As at Mar 31, 2024	Depreciation				W.D.V. As at Mar 31, 2024	W.D.V. As at March 31, 2023
						As at March 31, 2023	For the period	On disposals	As at Mar 31, 2024		
1	Intangible Assets	60.71		-	60.71	60.71	0.00	0	60.71	-0.00	-
	<b>Total</b>	<b>60.71</b>	<b>-</b>	<b>-</b>	<b>60.71</b>	<b>60.71</b>	<b>-</b>	<b>0</b>	<b>60.71</b>	<b>-0.00</b>	<b>-</b>

**Note:12B: Fixed Asset-Capital Work in Progress**

Sr. No.	Particulars	Gross Block As at March 31, 2023	Additions	Transferred to Fixed Assets	Gross Block As at Mar 31, 2024	Gross Block As at March 31, 2023
1	Capital WIP	1,388.60	81.32		1,469.93	1,388.60
	<b>Total</b>	<b>1,388.60</b>	<b>81.32</b>	<b>-</b>	<b>1,469.93</b>	<b>1,388.60</b>



CIAN HEALTHCARE LIMITED  
MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,  
C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT  
PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308  
CIN: L24233PN2003PLC017563

NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE PERIOD ENDING ON MARCH 31, 2024

Note 12:- Depreciation as per Income Tax Act

(Rs. In Lakhs)

SR.	DESCRIPTION OF ASSETS	RATE OF DEPRECIATION	GROSS BLOCK				Sale of Assets/subsidiy	Additional Depreciation	Depreciation for the Year	Total Depreciation for the Year	NET BLOCK		
			AS ON 01.04.2023	ADDITIONS		AS ON 31.03.2024					AS ON 31.03.2024	AS ON 31.03.2024	AS ON 31.03.2023
				For more than 180 days	For less than 180 days								
1	Furniture, Fixtures & Electrical Fittings	10%	146.27			146.27		14.63	14.63	131.65	146.27		
2	Machinery	15%	946.42	8.93	4.78	960.13		143.66	143.66	816.47	946.42		
3	Motor Vehicle	15%	45.09	-	-	45.09		6.76	6.76	38.32	45.09		
4	Computer	40%	3.21	1.00		4.21		1.68	1.68	2.53	3.21		
5	Trademark & goodwill	25%	5.21			5.21		1.30	1.30	3.91	5.21		
6	Building	10%	1,384.44			1,384.44		138.44	138.44	1,245.99	1,384.44		
	<b>Total</b>		<b>2,530.63</b>	<b>9.93</b>	<b>4.78</b>	<b>2,545.34</b>	-	-	<b>306.48</b>	<b>306.48</b>	<b>2,238.86</b>	<b>2,530.63</b>	



CIAN HEALTHCARE LIMITED  
MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,  
C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT  
PHURSUNGI, TAL. HAVELI, DIST. PUNE-412308  
CIN: L24233PN2003PLC017563

NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE PERIOD  
ENDING ON MARCH 31, 2024

Particulars	(Rs. In Lakhs)	(Rs. In Lakhs)
	As at Mar 31, 2024	As at March 31, 2023
<b>Note 13: Non-Current Investment</b>		
<u>Investments</u>		
(a) Investment in equity instruments of Wholly owned Subsidiary Fully Paid up Equity Shares on Dr. Smiths Biotech Private Limited (22,00,000 Unquoted Equity Shares having Face Value of Rs. 10.00 each , acquired at Rs. 32.22 Each)	708.84	708.84
<b>Total</b>	<b>708.84</b>	<b>708.84</b>

The Company has acquired 22,00,000 unquoted equity shares of Dr. Smiths Biotech Private Limited funded by proceeds from IPO

Particulars	(Rs. In Lakhs)	(Rs. In Lakhs)
	As at Mar 31, 2024	As at March 31, 2023
<b>Note 14: Long Term Loans and Advances</b>		
<u>(a) Capital advances *</u>		
Secured, considered good	107.16	73.88
Unsecured, considered good		
Doubtful		
<b>Total</b>	<b>107.16</b>	<b>73.88</b>
Less: Provision for doubtful advances	-	-
	<b>107.16</b>	<b>73.88</b>
<u>(b) Security deposits</u>		
Secured, considered good		
Unsecured, considered good		
Doubtful	-	-
Less: Provision for doubtful deposits	-	-
	-	-
<u>(c) Loans and advances to related parties (Refer Note 30.7)</u>		
Secured, considered good	-	-
Unsecured, considered good		
Doubtful	-	-
Less: Provision for doubtful loans and advances	-	-
	-	-
<u>(d) Balances with government authorities</u>		
Unsecured, considered good		
(i) CENVAT credit receivable		
(ii) VAT credit receivable		
(iii) Service Tax credit receivable		
	-	-
<u>(e) Long Term Advance given to others</u>		
Secured, considered good	1,000.00	1,000.00
Unsecured, considered good	9.50	7.65
Doubtful		
	<b>1,009.50</b>	<b>1,007.65</b>
<b>Total</b>	<b>1,116.66</b>	<b>1,081.53</b>



**CIAN HEALTHCARE LIMITED**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308**  
**CIN: L24233PN2003PLC017563**

NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE PERIOD  
ENDING ON MARCH 31, 2024

Note 15: Other Non-Current Assets	(Rs. In Lakhs)	(Rs. In Lakhs)
Particulars	As at Mar 31, 2024	As at March 31, 2023
(a) Long-term trade receivables # (including trade receivables on deferred credit terms) *Refer Note 29 i) for ageing Debtors Secured, considered good Unsecured, considered good Doubtful  Less: Provision for doubtful trade receivables		
(b) Unamortised expenses (i) Ancillary borrowing costs (ii) Share issue expenses (where applicable) (iii) Discount on shares (where applicable) (iv) Security Deposit Secured, considered good	1,802.05	1,005.41
	127.27	113.06
	1,929.32	1,118.47
<b>Total</b>	<b>1,929.32</b>	<b>1,118.47</b>

Note 16: Current Investments	(Rs. In Lakhs)	(Rs. In Lakhs)
Particulars	As at Mar 31, 2024	As at March 31, 2023
<b>Total</b>		



**CIAN HEALTHCARE LIMITED**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308**  
**CIN: L24233PN2003PLC017563**

**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE PERIOD ENDING ON MARCH 31, 2024**

Note 17: Inventories	(Rs. In Lakhs)	
	As at Mar 31, 2024	As at March 31, 2023
Particulars		
(a) Raw Material	376.87	265.96
(b) Work-in-progress	1,629.44	1,645.37
(c) Finished goods (Manufactured)	858.76	472.26
(d) Stock-in-trade (acquired for trading Including Packing Material for FY 2023-24)	902.81	208.29
(e) Packing Material	-	889.11
<b>Total</b>	<b>3,767.88</b>	<b>3,480.99</b>

Note 18: Trade Receivable	(Rs. In Lakhs)	
	As at Mar 31, 2024	As at March 31, 2023
Particulars		
Trade receivables outstanding for a period exceeding six months from the Secured, considered good		
Unsecured, considered good	971.19	981.69
Doubtful	11.05	11.05
	982.24	992.74
Less: Provision for doubtful trade receivables	-	-
	982.24	992.74
Other Trade receivables		
Secured, considered good		
Unsecured, considered good	848.17	1,361.18
Doubtful	848.17	1,361.18
Less: Provision for doubtful trade receivables	-	-
	848.17	1,361.18
<b>Total</b>	<b>1,830.41</b>	<b>2,353.92</b>

Note: Trade receivables include debts due from:	(Rs. In Lakhs)	
	As at Mar 31, 2024	As at March 31, 2023
Particulars		
(i) Directors		
(ii) Other officers of the Company		
(iii) Firms in which any director is a partner		
Unilink Marketing LLP		1.58
(iv) Private companies in which any director is a director or member		
Dr. Smiths Biotech Private Limited		1.39
<b>Total</b>	<b>-</b>	<b>2.97</b>



**CIAN HEALTHCARE LIMITED**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308**  
**CIN: L24233PN2003PLC017563**

**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE PERIOD ENDING ON MARCH 31, 2024**

**Note 19: Cash and Cash Equivalent**

Particulars	(Rs. In Lakhs)	(Rs. In Lakhs)
	As at Mar 31, 2024	As at March 31, 2023
(a) Cash in Hand	4.67	11.02
(b) Cheques, drafts on hand	-	-
(c) Balances with banks		
(i) In current accounts	9.51	22.99
(ii) In EEFC accounts	-	-
(iii) In deposit accounts	58.56	78.56
(Refer Note for changes )		
<b>Total</b>	<b>72.74</b>	<b>112.57</b>

**Note 20: Short Term Loans and Advances**

Particulars	(Rs. In Lakhs)	(Rs. In Lakhs)
	As at Mar 31, 2024	As at March 31, 2023
(a) Loans and advances to related parties		
Secured, considered good		
Unsecured, considered good		
Doubtful	0	0
Less: Provision for doubtful loans and advances	0	0
(b) Security deposits		
Secured, considered good		
Unsecured, considered good		
Doubtful	0	0
Less: Provision for doubtful deposits	0	0
(c) Loans and advances to employees		
Secured, considered good		
Unsecured, considered good- Salary	2.78	2.26
Unsecured, considered good- Imprest	-	2.41
Doubtful	2.78	4.68
Less: Provision for doubtful loans and advances	2.78	4.68
(d) Loans and advances to Others		
Secured, considered good		
Unsecured, considered good	3.50	-
Doubtful	3.50	-
Less: Provision for doubtful deposits	3.50	-
(e) Prepaid expenses - Unsecured, considered good	3.77	5.00
(f) Balances with government authorities		
Unsecured, considered good		
(i) CENVAT credit receivable	-	-
(ii) VAT & CST credit receivable	53.97	63.30
(iii) Service Tax credit receivable	-	-
(iv) GST credit available	299.60	293.85
(v) TDS Receivable	20.00	25.58
(vi) MAT Credit Available	18.93	-
(vii) Advance Tax	-	-
(viii) TDS on GST Available	46.57	49.86
	439.08	432.58
<b>Total</b>	<b>449.13</b>	<b>442.26</b>



CIAN HEALTHCARE LIMITED  
MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,  
C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT  
PHURSUNGI, TAL. HAVELLDIST. PUNE-412308  
CIN: L24233PN2003PLC017563

NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE PERIOD ENDING ON MARCH 31, 2024

Note 21: Other Current Assets	(Rs. In Lakhs)	(Rs. In Lakhs)
Particulars	As at Mar 31, 2024	As at March 31, 2023
Advance to Sundry Creditors-RM, PM, FG*	323.40	383.03
Advance to Sundry Creditors-Expenses*	31.87	50.65
Inter Branch Balances	0.66	0.57
*Refer Note 29 i) for ageing of Advances to creditors		
<b>Total</b>	<b>355.93</b>	<b>434.24</b>

Note: Advances to Sundry creditors- RM, PM, FG include advances given to	(Rs. In Lakhs)	(Rs. In Lakhs)
Particulars	As at Mar 31, 2024	As at March 31, 2023
(i) Directors		
(ii) Other officers of the Company		
(iii) Firms in which any director is a partner Unilink Marketing LLP		
(iv) Private companies in which any director is a director or member Dr. Smiths Biotech Private Limited	-	-
<b>Total</b>	<b>-</b>	<b>-</b>



**CIAN HEALTHCARE LIMITED**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308**  
**CIN: L24233PN2003PLC017563**

**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE PERIOD ENDING ON MARCH 31, 2024**

<b>Note 22: Revenue from Operations</b>	(Rs. In Lakhs)	(Rs. In Lakhs)
<b>Particulars</b>	<b>For the year ended March 31, 2024</b>	<b>For the year ended March 31, 2023</b>
Sales-Domestic	5,105.21	5,887.03
Export Sales	1,079.27	967.02
Less: Goods Return	309.59	97.93
<b>Total Revenue from Operations</b>	<b>5,874.89</b>	<b>6,756.13</b>

<b>Note 23: Other Income</b>	(Rs. In Lakhs)	(Rs. In Lakhs)
<b>Particulars</b>	<b>For the year ended March 31, 2024</b>	<b>For the year ended March 31, 2023</b>
Interest on Fixed Deposits	3.42	4.56
Export scheme Benefits-MEIS/FMS	5.60	1.05
Realised Exchange Gain/Loss	5.06	7.00
Unrealised Exchange Gain/Loss	9.40	30.04
Export Duty Drawback	14.01	9.64
Discount	-	0.13
Miscellaneous Income	0.63	1.39
Interest on other deposits	-	-
Income - Services	67.97	-
<b>Total Other Income</b>	<b>106.08</b>	<b>53.81</b>





**CIAN HEALTHCARE LIMITED**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308**  
**CIN: L24233PN2003PLC017563**

**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE PERIOD ENDING ON MARCH 31, 2024**

Note 24.a : Cost of Material Consumed	(Rs. In Lakhs)	(Rs. In Lakhs)
Particulars	For the year ended March 31, 2024	For the year ended March 31, 2023
Opening Stock during the Year		
Raw Material	265.96	706.23
Packing Material	889.11	854.40
	<b>1,155.07</b>	<b>1,560.63</b>
Add: Purchases during the period		
Raw Material	2,230.77	2,128.00
Packing Material	1,139.41	1,035.49
Custom Charges	-	-
	<b>3,370.18</b>	<b>3,163.49</b>
Less: Closing Stock during the Year		
Raw Material	376.87	265.96
Packing Material	-	889.11
	<b>376.87</b>	<b>1,155.07</b>
<b>Total Cost of Material consumed</b>	<b>4,148.38</b>	<b>3,569.05</b>

Note 24.b : Purchases of Trading Goods	(Rs. In Lakhs)	(Rs. In Lakhs)
Particulars	For the year ended March 31, 2024	For the year ended March 31, 2023
Purchases- Finished Goods	524.79	1,011.34
Purchases- Finished Goods-Sangli	-	-
Purchases-TR- Expenses	-205.43	-
Sample Purchases	0.15	0.09
<b>Total</b>	<b>319.51</b>	<b>1,011.44</b>

Note 24.c Changes in inventories of finished goods, work-in-	(Rs. In Lakhs)	(Rs. In Lakhs)
Particulars	For the year ended March 31, 2024	For the year ended March 31, 2023
Inventories at the end of the year:		
Finished goods	858.76	472.26
Work-in-progress	1,629.44	1,645.37
Stock-in-trade (acquired for trading Including Packing Material for FY 2023-24)	902.81	208.29
	<b>3,391.01</b>	<b>2,325.92</b>
Inventories at the beginning of the year:		
Finished goods	472.26	355.42
Work-in-progress	1,645.37	1,202.01
Stock-in-trade	208.29	283.63
	<b>2,325.92</b>	<b>1,841.06</b>
<b>Net Increase/Decrease in the Year</b>	<b>-1,065.09</b>	<b>-484.86</b>



CIAN HEALTHCARE LIMITED  
MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,  
C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT  
PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308  
CIN: L24233PN2003PLC017563

NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE PERIOD ENDING ON MARCH 31, 2024

Note 25: Other Operating Expenses	(Rs. In Lakhs)	(Rs. In Lakhs)
Particulars	For the year ended March 31, 2024	For the year ended March 31, 2023
Transportation Charges	84.61	77.84
Other Charges/Direct Expenses	331.81	327.83
<b>Total</b>	<b>416.42</b>	<b>405.67</b>

Note 26: Employee Benefit Expenses	(Rs. In Lakhs)	(Rs. In Lakhs)
Particulars	For the year ended March 31, 2024	For the year ended March 31, 2023
Salaries and Wages	632.86	693.84
Directors Remuneration	41.29	30.34
Contribution / provisions to and for provident, Gratuity and other funds	62.02	61.82
Staff welfare expenses	23.43	19.92
<b>Total</b>	<b>759.60</b>	<b>805.91</b>

Note 27: Finance Costs	(Rs. In Lakhs)	(Rs. In Lakhs)
Particulars	For the year ended March 31, 2024	For the year ended March 31, 2023
Interest Expenses		
On Term Loan	103.75	112.00
On Vehicle Loan	2.32	3.62
On Cash Credit	329.75	292.47
Other Financial Expenses	36.95	10.37
(Includes Bank Charges, Loan Processing Fess and other Finance Charges)		
<b>Total</b>	<b>472.76</b>	<b>418.45</b>



**CIAN HEALTHCARE LIMITED**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308**  
**CIN: L24233PN2003PLC017563**

**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE PERIOD  
ENDING ON MARCH 31, 2024**

**Note 28: Other Admin Expenses**


(Rs. In Lakhs) (Rs. In Lakhs)

Particulars	For the year ended March 31, 2024	For the year ended March 31, 2023
Rent Expenses	35.42	49.97
Other Admin Expenses	93.30	50.83
Commission and Discount Expenses	45.09	53.37
Security Charges	12.40	13.24
Electricity Expenses	6.70	6.80
Insurance Expenses	6.98	13.46
Office Expenses	4.53	4.20
Printing & Stationery	7.54	11.47
Professional Fee	53.06	19.19
Repairs & Maintenance	55.72	44.82
Travelling & Conveyance	71.33	54.59
Internet & Telephone Expenses	5.03	4.75
Interest & Penalty on Taxes	20.63	60.65
GST Reversal A/c	-	-
Legal Expenses	6.36	6.60
Product Registration Charges	15.83	6.78
Sales Promotion & Advertisement Expenses	17.31	22.64
Service Charges	0.65	0.39
Directors Fees	-	8.00
Waste Disposal Expenses	1.04	1.19
CSR Fund Utilization	-	-
Amortization of Deferred Expenses	94.84	159.59
Recruitment Charges	0.38	1.91
Audit Fees	4.50	6.00
General Expenses	0.63	2.41
Factory Expenses	-	0.30
Statutory dues	0.88	-
<b>Total</b>	<b>560.14</b>	<b>603.14</b>

**Notes:**

**1. Payment to Auditors includes**

Particulars	For the year ended March 31, 2024	For the year ended March 31, 2023
As auditors - Statutory Audit	4.50	4.50
For Company Law Matter		
For Tax Audit	2.00	2.00
For Reimbursement of Expenses		
For Certification Charges	-	-
For Other Services		
<b>Total</b>	<b>6.50</b>	<b>6.50</b>



**CIAN HEALTHCARE LIMITED**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308**  
**CIN: L24233PN2003PLC017563**

**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE PERIOD ENDING ON MARCH 31, 2024**

**Note 29. a) Exceptional Items**

There are no Exceptional Items to be disclosed

**Note 29. b) Extraordinary Items**

Particulars	For the Year Ended March 31, 2024	For the Year Ended March 31, 2023
Prior period Income	-0.85	-1.08
Prior period Expenses	0.65	7.85
	<b>-0.20</b>	<b>6.77</b>

**Note 29. c) Details on derivatives instruments and unhedged foreign currency exposures**

The year-end foreign currency exposures that have not been hedged by a derivative instrument or otherwise are given below:

Particulars	For the Year Ended March 31, 2024 (In Foreign Currency in Lakhs)	For the Year Ended March 31, 2023 (In Foreign Currency in Lakhs)	For the Year Ended March 31, 2024 (Rs. In Lakhs)(Restated)	For the Year Ended March 31, 2023 (Rs. In Lakhs) (Restated)
Receivable from Debtors	\$3.51	\$7.21	292.27	592.97
Advance received from Debtors	-\$1.73	-\$1.89	-144.56	-155.46
Receivable from Debtors	€ 0.00	€ 0.04	-	3.78
Advance received from Debtors	€ -0.16	€ -0.16	-14.36	-14.36

**Note 29 d) Expenditure in Foreign Currency**

Particulars	For the Year Ended March 31, 2024	For the Year Ended March 31, 2023 (Rs. In Lakhs)
Royalty		
Know-how		
Professional and consultation fees		
Interest		
Raw Material Purchases		
Product Registration Charges	-	0.75

**Note 29 e) Details of consumption of imported and indigenous items \***

Particulars	For the Year Ended March 31, 2024 (Rs. In Lakhs)	For the Year Ended March 31, 2023 (Rs. In Lakhs)
Imported		
Raw materials	-	-

**Note 29 f) Earnings in foreign exchange**

Particulars	For the Year Ended March 31, 2024 (Rs. In Lakhs)	For the Year Ended March 31, 2023 (Rs. In Lakhs)
Sales in Foreign currency	1,078.63	844.08

The Financial statements are presented in Indian Rupees, which is the functional currency of the Company.

Transactions in currencies other than the company's functional currency are recognized at the exchange rate prevailing on the date of transaction. Monetary assets and liabilities are denominated in foreign currencies are translated into the functional currency at the closing exchange rate prevailing as at the reporting date. Non- Monetary assets and liabilities denominated in a foreign currency are translated using the exchange rate prevailing at the date of initial recognition (in case measured at historical cost) or at the rate prevailing at the date when the fair value is determined (in case measured at the fair value)

Foreign exchange differences are recognised in profit and loss in the period in which they arise except for the exchange difference on foreign currency borrowings related to assets under construction for future productive use, which are included in the cost of those assets when they are regarded as an adjustment to interest cost on those foreign currency borrowings

**29 g) Details of unutilised amounts out of issue of securities made for specific purpose**



**29 h) Disclosures required under Section 22 of the Micro, Small and Medium Enterprises Development Act, 2006**

Particulars	For the year ended March 31, 2024	For the Year Ended March 31, 2023
(i) Principal amount remaining unpaid to any supplier as at the end of the accounting year		
A) Micro	168.76	
B) Small	400.29	
C) Medium	325.91	

The company has duly filed MSME-I for the period April-23 to March-24 as per the prescribed format and disclosed all the required details.

Above outstanding not includes the amount payable to Capital Creditors also which is included in Note: 14: Long Term Loans and Advances (Capital Advances) and others included in Trade payables which includes payable for RM, FG & other Expenses.

Dues to Micro and Small Enterprises have been determined to the extent such parties have been identified on the basis of information collected by the Management. This has been relied upon by the auditors.

**29 i) Ageing of Trade payable, Trade receivable, Advance to Creditors and Advance from Debtors**

Below Balances are subject to balance confirmations


A) Trade Payables		(Refer Note: 9)				
Particulars	Outstanding for following periods from due date of payment					Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years		
1) MSME	474.22	127.70	274.93	18.11		894.96
2) Others	1,075.89	315.02	188.55	39.56		1,619.02
3) Disputed Dues						
a) MSME			-	-		-
b) Others			-	-		-
<b>Total</b>	<b>1,550.10</b>	<b>442.72</b>	<b>463.48</b>	<b>57.67</b>		<b>2,513.98</b>

\* We have not booked interest provision of MSME dues above 45 Days

B) Trade receivables		(Refer Note: 18)					(Rs. In Lakhs)
Particulars	Outstanding for following periods from due date of payment					Total	
	Less than 6 months	6 months -1 year	1-2 years	2-3 years	More than 3 years		
(i) Undisputed Trade receivables – considered good	848.17	218.65	68.47	175.46	508.62	1,819.36	
(ii) Undisputed Trade Receivables – considered doubtful					-	-	
(iii) Disputed Trade Receivables considered good	-	-	-	-	-	-	
(iv) Disputed Trade Receivables considered doubtful	-	-	-	-	11.05	11.05	
<b>Total Rs.</b>	<b>848.17</b>	<b>218.65</b>	<b>68.47</b>	<b>175.46</b>	<b>519.67</b>	<b>1,830.41</b>	

C) Advance to Creditors		(Refer Note: 21)				
Particulars	Outstanding for following periods from due date of payment					Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years		
1) MSME	188.79	1.05	0.77	0.39		190.99
2) Others	96.77	17.22	3.98	46.31		164.27
3) Disputed Advances						
a) MSME	-	-	-	-		-
b) Others	-	-	-	-		-
<b>Total</b>	<b>285.55</b>	<b>18.26</b>	<b>4.75</b>	<b>46.70</b>		<b>355.27</b>

D) Advance from Debtors		(Refer Note: 10)					(Rs. In Lakhs)
Particulars	Outstanding for following periods from due date of payment					Total	
	Less than 6 months	6 months -1 year	1-2 years	2-3 years	More than 3 years		
(i) Undisputed Trade receivables – considered good	139.65	99.44	0.00	3.10	80.29	322.48	
(ii) Undisputed Trade Receivables – considered doubtful					0	0	
(iii) Disputed Trade Receivables considered good	-	-	-	-	-	-	
(iv) Disputed Trade Receivables considered doubtful	-	-	-	-	-	-	
<b>Total Rs.</b>	<b>139.65</b>	<b>99.44</b>	<b>-</b>	<b>3.10</b>	<b>80.29</b>	<b>322.48</b>	



29 j) Corporate Social Responsibility (CSR) Where the company covered under section 135 of the companies act

Particulars	(Rs. In Lakhs)	(Rs. In Lakhs)
	For the Year Ended March 31, 2024	For the Year Ended March 31, 2023
1) Amount Required To Be Spent By The Company During The Year	NA	NA
2) Amount Of Expenditure Incurred	NA	NA
3) Shortfall At The End Of The Year	NA	NA
4) Total Of Previous Years Shortfall	NA	NA
5) Total Shortfall	NA	NA
6) Reason For Shortfall	NA	NA
7) Nature Of CSR Activities	NA	NA
8) Details Of Related Party Transactions	NA	NA
9) Where A Provision Is Made With Respect To A Liability Incurred	NA	NA

**Nature of CSR Activities:**

CSR funds spend by the company for the activities mentioned Schedule 7 clause (i) (i.e. Eradicating hunger, poverty and malnutrition, <sup>2</sup>[“promoting health care including preventive health care”] and sanitation <sup>4</sup>[including contribution to the Swach Bharat Kosh set-up by the Central Government for the promotion of sanitation] and making available safe drinking water) in this COVID-19 pandemic is eligible for considering it as CSR activity

**29 k) Other Disclosures related to Taxes payables and demands**

There are no material dues of income tax or sales tax or service tax or duty of customs or duty of excise or value added tax which have not been deposited with

Name of the Statute	Nature of Dues	F.Y	Amount disputed not yet deposited (Rs. in Lakhs)	Forum where dispute is



CIAN HEALTHCARE LIMITED  
MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,  
C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT  
PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308  
CIN: L24233PN2003PLC017563

NOTES FORMING PART OF THE STANDALONE PROVISIONAL FINANCIAL STATEMENTS FOR THE PERIOD ENDED ON MARCH 31, 2024

Note 30 Disclosures under Accounting Standards

30.01 AS-7: Details of contract revenue and costs

Particulars	For the Year Ended March 31, 2024 (Rs. In Lakhs)	For the Year Ended March 31, 2022 (Rs. In Lakhs)
Contract revenue recognised during the year	-	-
Advances received for contracts in progress	-	-
Retention money for contracts in progress	-	-
Gross amount due from customers for contract work (asset)	-	-
Gross amount due to customers for contract work (liability)	-	-

30.02 AS-12: Details of government grants

Particulars	For the Year Ended March 31, 2024 (Rs. In Lakhs)	For the Year Ended March 31, 2022 (Rs. In Lakhs)
Government grants received by the Company during the year towards		
- Subsidies (recognised under Fixed Assets)	-	6.90
- Duty drawback (recognised under Other operating revenues)	14.01	
- Other incentives-MEIS	5.60	12.60

30.03 AS-13: Accounting for Investment

Particulars	For the Year Ended March 31, 2024 (Rs. In Lakhs)	For the Year Ended March 31, 2023 (Rs. In Lakhs)
The company has acquired 100% Unquoted Equity shares of Dr. Smiths Biotech Private Limited The same is accounted at cost by the company under non current investment (22,00,000 Equity Shares of face value Rs. 10 Each at Rs.32.22 each during the year 2019-20 )	-	-

30.04 AS-14: Accounting for Amalgamations

The company has not entered in to any amalgamation transactions, hence the AS-14 for Accounting for Amalgamation is Not Applicable

30.05 AS-15: Employee Benefits

i) Short Term Employee Benefits

Short term employee benefits are expensed as & when the related service is provided. A liability is recognized for the amount expected to be paid if the company has existing legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.

ii) Long-Term Employee Benefits

The liability for the earned leave is not expected to be settled wholly within twelve months after the end of the period in which the employees render the related service. They are therefore measured as the present value of expected future payments to be made in respect of services provided by employees upto the end of reporting period with actuarial valuations being carried out at each balance sheet date. The benefits are discounted using market yields at the end of the reporting period that have terms approximating to the terms of the related obligations.

iii) Post Employment Benefits

a) Defined Contribution Plan

Payments to defined contribution retirement benefit plans are recognised as expenses when the employees have rendered the service entitling themselves to the contribution.

Provident Fund: The employees of the company are entitled to receive the benefits in respect of provident fund, a defined contribution plan, in which both employees and the company make monthly contributions at a specific percentage of the covered employees salary ( currently 12% of employee's salary) The contributions are made only for those employees whose salary is below or at par with the limit prescribed by the law. The contributions as specified under the law are made to the provident fund and pension fund administer by Regional Provident Fund Commissioner The Company recognises the such contributions as and expenses when incurred.

b) Defined Benefit Plans


For defined benefit retirement plans, the cost of providing benefits is determined using the projected unit credit method, with actuarial valuations being carried out at the end of each annual reporting period. Re-measurements, comprising actuarial gains and losses, the effect of changes to asset ceiling (if applicable) and the return on plan assets (excluding net interest), is recognised in profit and loss account for the period in which they occurs.

Defined benefit costs comprising service cost (including current and past service cost and gains and losses on curtailments and settlements) and net interest expenses or income is recognised in profit and loss.

The defined benefit obligation recognised in the balance sheet represents the actual deficit or surplus in the company's defined benefit plans. Any surplus resulting from this calculation is limited to the present value of any economic benefits available in the form of refunds from the plans or reductions in future contributions to the plan.

The obligations are presented as a current liabilities in the balance sheet in the entity does not have an unconditional right to defer the settlement for at least twelve months after the reporting period, regardless of when actual settlement is expected to occurs.

Gratuity: The company has an obligation towards gratuity, a defined benefit retirement plan covering eligible employees. The plan provides lump sum payments to vested employees at retirement, death while in employment or on termination of employment of an amount as per the provisions of the Payment of Gratuity Act,1972. Vesting occurs upon completion of five years of service. The company accounts for the liability method.



CIAN HEALTHCARE LIMITED  
MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,  
C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT  
PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308  
CIN: L24233PN2003PLC017563

NOTES FORMING PART OF THE STANDALONE PROVISIONAL FINANCIAL STATEMENTS FOR THE PERIOD ENDED ON MARCH 31, 2024

Particulars	Gratuity Benefit		Earned/Privilege Leave benefit	
	For the Year Ended March 31, 2024 (Rs. In Lakhs)	For the Year Ended March 31, 2022 (Rs. In Lakhs)	For the Year Ended March 31, 2023 (Rs. In Lakhs)	For the Year Ended March 31, 2022 (Rs. In Lakhs)
<b>Components of employer expense</b>				
Current service cost	20.20	23.79	6.98	11.97
Interest cost	6.40	5.63	1.12	0.87
Expected return on plan assets	-	-	-	-
Curtailment cost / (credit)	-	-	-	-
Settlement cost / (credit)	-	-	-	-
Past service cost	-	-	-	-
Actuarial losses/(gains)	-10.87	-11.03	-2.08	-5.75
<b>Total expense recognised in the Statement of Profit and Loss</b>	<b>15.73</b>	<b>17.36</b>	<b>6.02</b>	<b>2.68</b>
<b>Actual contribution and benefit payments for year</b>				
Actual benefit payments	11.21	10.47	2.20	3.45
Actual contributions	-	-	-	-
<b>Net asset / (liability) recognised in the Balance Sheet</b>				
Opening Defined Benefit Obligation	89.37	81.44	19.45	15.81
Transfer in/(out) obligation	-	-	-	-
Current service cost	20.20	23.79	6.98	11.97
Interest cost	6.40	5.63	1.12	0.87
Actuarial loss (gain)	-10.87	-11.03	-2.08	-5.75
Unrecognised past service costs	-	-	-	-
Past service cost	-	-	-	-
Loss (gain) on curtailments	-	-	-	-
Liabilities extinguished on settlements	-	-	-	-
Liabilities assumed in an amalgamation in the nature of purchase	-	-	-	-
Exchange differences on foreign plans	-	-	-	-
Benefits paid	-11.21	-10.47	-2.20	-3.45
<b>Net asset / (liability) recognised in the Balance Sheet</b>	<b>93.89</b>	<b>89.37</b>	<b>23.27</b>	<b>19.45</b>

iv) Employee Stock Option Plan (ESOP)

Company has not announced any employee stock option scheme during the year.

30.06 AS-16: Borrowing Cost

Particulars	For the Year Ended March 31, 2024 (Rs. In Lakhs)	For the Year Ended March 31, 2023 (Rs. In Lakhs)
<b>Details of borrowing costs capitalised</b>		
Borrowing costs capitalised during the year		
Borrowing costs capitalised during the year - as inventory	81.32	78.50

30.07 AS-17: Segment Reporting

Considering the nature of Company's business, there is only one reportable segment in accordance with the requirement of AS-17 on "Segment Reporting", hence separate disclosure of the segment information is not considered necessary.

30.09 AS-19: Details of leasing arrangements

Not Applicable

30.10 AS-20: Earning Per Share

Cian Healthcare Limited does not have any discontinued operations or any type of preferential or Diluted Equity, Hence only basic EPS is calculated

Particulars		For the Year Ended March 31, 2024	For the Year Ended March 31, 2023
Profit for the Year	(Rs. In Lakhs)	38.96	107.68
Equity Shares	(No. In Lakhs)	249.96	249.96
<b>Earning per Share</b>	(Rs. In Lakhs)	<b>0.16</b>	<b>0.43</b>





CIAN HEALTHCARE LIMITED  
MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,  
C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT  
PHURSUNGI, TAL. HAVELI.DIST. PUNE-412308  
CIN: L24233PN2003PLC017563

NOTES FORMING PART OF THE STANDALONE PROVISIONAL FINANCIAL STATEMENTS FOR THE PERIOD ENDED ON MARCH 31, 2024

**30.11 AS-22: Deferred Tax Assets/Liability**

Method II

Particulars	For the Year Ended March 31, 2024	For the Year Ended March 31, 2023
Deprecation as per Companies Act 2013	368.19	256.80
Deprecation as per Income Tax Act 1961	306.48	210.45
Timing Difference (Asset) on Depreciation	-61.71	-46.35
<b>Disallowances</b>		
Disallowance as per Income Tax Act	11.25	10.63
Timing Difference (Asset) on Disallowances	-11.25	10.63
<b>Total Timing Difference</b>	-72.96	-35.72
<b>Tax Rate</b>	26%	28%
Deferred Tax (Assets)/ liability to be debited to Profit and Loss	-18.97	-9.94
Deferred Tax (Assets)/ liability at the beginning of the year	110.17	127.79
Closing Deferred tax (Asset)/Liability to be Carried to Balance Sheet	91.21	110.17

**30.12 AS-24: Discontinued Operations**

The company has not discontinued any operations during the year.

**30.13 AS-26: Details of research and development expenditure recognised as an expense**

Cian HealthCare Limited has not spent any amount for Research and Development which is considered as an expenses during the Year

**30.14 AS-27: Interest in Joint Ventures**

Cian HealthCare Limited has not entered in any joint ventures contract during the Year

**30.15 AS-29: Provisions, Contingent Liabilities and Contingent Assets**

**Provisions:**

Provisions are recognized only when there is a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate can be made.

**Contingent liability:**

- a) Possible obligations which will be confirmed only by future events not wholly within the control of the company, or
- b) Present obligations arising from past events where it is not probable that an outflow of resources will be required to settle the obligation or a reliable estimate of the amount of the obligation cannot be made.

**Contingent Assets**

A contingent asset is a possible asset that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company. Contingent assets are not recognised and disclosed only when an inflow of economic benefits is probable.



**CIAN HEALTHCARE LIMITED**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308**  
**CIN: L24233PN2003PLC017563**

**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE PERIOD ENDED ON MARCH 31, 2024**

Note: 30.08

AS 18: Related Party Transaction

**List of Directors**

Sr. No.	Name	Address	Designation	PAN No.	DIN	Date of Appointment	Date of Birth	Date of Resignation/Caseation
1	Suraj Shriniwas Zanwar	D1, 2057, 5th Floor, Shobha Carnation, Kondhwa (BK), Pune-411048 Maharashtra, India	Managing Director	AAAPZ8628H	1304850	1/7/2003	1/31/1975	
2	Paresh Shah	House No. 210, Solapur Bazar , Opp: Poolgate Bus Stop, Camp Pune-411001 MH IN	Non Executive Director	BEBPS1960M	8502901	8/25/2022	7/17/1979	
3	Swati Maheshwari	A-303, KAKAD PARADISE, OPP GANESH TEMPLE, PENKARPADA, MIRA ROAD, THANE 401107	Independent Director	AQKPM6024E	7268922	5/30/2022	12/16/1987	
4	Sunil Kumar	49, AT POST FATEHPUR BHADO, SAHARANPUR 247662 UP	Independent Director	BFOPK0457F	9716226	9/3/2022	7/4/1978	
5	Damodar Sharma	G-1/16 , Konark Enclave, Khare Tarkunde Nagar , Katod Road, Nagpur - 440013	Executive Director	AMTPS0737P	7984882	10/16/2021	7/7/1970	7/12/2022
6	Mohammad Raees Sheikh	213, Azad Nagar Goli -Karkhana Indore 452001 MP IN	Independent Director	BDAPS9057D	6857879	6/2/2020	6/3/1975	3/30/2022
7	Shikha Rai	8, Tara Chand Dutta Street Kolkata Chittaranjan Avenue S.O, Chittaranjan Avenue Kolkata West Bengal-700073	Independent Director	CUSPR4537B	8202841	7/28/2020	11/28/1992	2/25/2022
8	Riyaz Bashir Khan	Ashoka Mews, K-Building, Flat No. 107, Kondhwa, Pune-411048 Maharashtra, India	Whole-time Director	BCWPK1529B	7578366	7/29/2016	11/24/1984	10/16/2021
9	Santosh Shivaji Pimpalkar	Nighoj, Ahmadnagar-414061, MH, IN	Director	ASXPP6449F	8466723	7/8/2019	2/14/1979	10/8/2022



**CIAN HEALTHCARE LIMITED**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308**  
**CIN: L24233PN2003PLC017563**

**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE PERIOD ENDED ON MARCH 31, 2024**

Note: 30.08

AS 18: Related Party Transaction

Key Management Personnel :								Date of Resignation/Caseation
Sr. No.	Name	Address	Designation	PAN No.	DIN	Date of Appointment	Date of Birth	
1	Suraj Shriniwas Zanwar	D1, 2057, 5th Floor, Shobha Carnation, Kondhwa (BK), Pune-411048 Maharashtra, India	Managing Director	AAAPZ8628H	1304850	1/7/2003	1/31/1975	
2	Paresh Shah	House No. 210, Solapur Bazar , Opp: Poolgate Bus Stop, Camp Pune-411001 MH IN	Non Executive Director	BEBPS1960M	8502901	8/25/2022	7/17/1979	
3	Swati Maheshwari	A-303, KAKAD PARADISE, OPP GANESH TEMPLE, PENKARPADA, MIRA ROAD, THANE 401107	Independent Director	AQKPM6024E	7268922	5/30/2022	12/16/1987	
4	Sunil Kumar	49, AT POST FATEHPUR BHADO, SAHARANPUR 247662 UP	Independent Director	BFOPK0457F	9716226	9/3/2022	7/4/1978	
5	Damodar Sharma	G-1/16 , Konark Enclave, Khare Tarkunde Nagar , Katod Road, Nagpur - 440013	Executive Director	AMTPS0737P	7984882	10/16/2021	7/7/1970	7/12/2022
6	Santosh Shivaji Pimpalkar	Nighoj, Ahmadnagar-414061, MH, IN	Director	ASXPP6449F	8466723	7/8/2019	2/14/1979	10/8/2022
7	Prateek Kulkarni	Flat No D-1/302, Nikash Lawns D-1, Co - Op. Hsg Society, S N 140/3, Near Datta Mandir, Behind Saraswat Bank, Pashan Sus Road, Pashan , Armament, Pune, Maharashtra 411021	Director	BACPK2551D	5133085	17/01/2024	4/9/1986	17/01/2024
8	Riyaz Bashir Khan	Ashoka Mews, K-Building, Flat No. 107, Kondhwa, Pune-411048 Maharashtra, India	CFO(KMP)	BCWPK1529B	7578366	6/12/2020	11/24/1984	
9	Mr.Munjaji Dhumal	D-6, Shankar Chaya, Erandwane Pune 411004	Company Secretary	CLTPD3486P	NA	7/30/2021	6/5/1994	



**CIAN HEALTHCARE LIMITED**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELL,DIST. PUNE-412308**  
**CIN: L24233PN2003PLC017563**

**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE PERIOD ENDED ON MARCH 31, 2024**

**Note 31: Previous Year's Figures**

These have been regrouped/reclassified as and where required

Below are the impacts of regrouping/Reclassification:-

A) We have reclassified advance received from customer- PFC Royal Rs. 20,00,000 under Trade Deposit under current liabilities group for the financial year 2023-24

B) We have reclassified Trade Payable & Trade Receivable schedule as per schedule-III Requirement

C) We have reclassified Tangible & Intangible Assets as "Property, Plant and Equipment & Intangible assets as per schedule-III Requirement

D) We have reclassified security Deposits under "Other non-current assets" from "Long-term loans and advances for the Fy 2023-24

**Note 32: Details of securities against Term Loans and Cash Credit facilities**

Bank Name	Lender Name	Amount of Loan	Principal Outstanding as on 31.03.2024	Rate of Interest	Mortgage/Securities given against loan
TERM LOAN-SIDBI-D0000THM	Term Loan	725.00	78.39	12.00%	Refer Annexure below
TERM LOAN-BOB A/C-71010600000191	Term Loan	137.50	54.55	12.15%	
TERM LOAN - IDBI BANK A/C- 0338	Term Loan	400.00	-	12.40%	
TERM LOAN - BOB A/C - 197	Term Loan	595.00	79.59	12.15%	
TERM LOAN - UBI A/C-7691	Term Loan	250.00	-	11.25%	
TERM LOAN - UBI A/C-7780	Term Loan	155.00	0.86	11.25%	
TERM LOAN - UBI A/C-8108	Term Loan	137.50	59.30	10.90%	
TERM LOAN - BOB - 0183	Term Loan	1,200.00	714.16	12.15%	
TERM LOAN-SIDBI-D0000UGJ	Risk Capital	300.00	185.51	14.45%	
TERM LOAN - BOB - FITL A/C- 968	Funded Interest Term Loan	15.00	5.34	BRLLR+0.75%	
TERM LOAN - BOB - FITL A/C- 969	Funded Interest Term Loan	5.10	1.78	BRLLR+0.75%	
TERM LOAN - UBI - FITL A/C- 001	Funded Interest Term Loan	20.00	-	MCLR+5%	
TERM LOAN - IDBI BANK FITL A/C- 2783	Funded Interest Term Loan	19.00	2.47	12.40%	
TERM LOAN - BOB - FITL A/C- 1240	Funded Interest Term Loan	70.00	18.98	BRLLR+0.75%	
TERM LOAN-SIDBI FITL-D0003QT7	Funded Interest Term Loan	15.44	3.93	14.70%	
TERM LOAN-SIDBI FITL-D0003QTC	Funded Interest Term Loan	25.07	8.49	12.25%	
IDBI BANK (C C) - 301651100000019	Cash Credit	1,240.00	1,226.64	11.40%	
BOB (C C) - 71010500000018	Cash Credit	340.00	347.95	11.15%	
UBI (C C) - 560101000005431	Cash Credit	570.00	578.03	10.50%	
TERM LOAN-YES BANK-BMW	Auto Loan	58.87	19.21	8.24%	
TERM LOAN-YES BANK-S-CROSS	Auto Loan	11.70	0.23	9.11%	MARUTI S-CROSS MH-12 QM 9591
TERM LOAN-YES BANK-INNOVA	Auto Loan	15.82	1.17	8.75%	INNOVA - UK-17 J 0500

**Annexure:-**

**Security :-**

**Primary:**

CC/ PC/ FBP/FBN/LC. Exclusive First pari passu charge by way of hypothecation of entire current assets of the Company including stock and debtors (present & future).

First Pari-passu charge on all the immovable and movable fixed assets of the Company (present and future) situated at Khasara No. 248 and 245, Village – Sisona, Bhagwanpur Roorkee- Haridwar Uttarakhand.

First pari – passu charge on proposed factory construction at Khasara no. 245, subplot nos. 1 & 2 + proposed Bldg. construction+ P & M worth Rs. 1927.58 lakh as per project cost.

**Collateral security:-Common for all credit facilities**

**Pari –Passu charge on:**

- Equitable Mortgage of Shop at Venkatesh Vardhan, CTS No 1766, Sr. No. 462/5 and R.S No. 461/2B Ganesh Nagar, Sangli owned by Shri Suraj Shrinivas Zanwar.
- Equitable Mortgage of plot No. C-6, MIDC, Wai, Taluka- Wai, Dist - Satara, Maharashtra admeasuring about 8600 sq mtrs including plant & machinery & the construction thereon if any.
- Equitable Mortgage at Residential Property situated at Flat No. 14, 1<sup>st</sup> & 2<sup>nd</sup> Floor, Amrapali Residency, Sant Nagar- Aranyeshwar Pune 411009 in the name of Shri. Pankaj Zanwar.
- Equitable Mortgage of Plot No. 9 and 20, S/No. 288/289, Radhika Road, Near Radhika Hotel, Satara, Owned by Shri Abhishek Radheshyam Bhandari, son of Shri Radheshyam Bhandari.
- FD of Shri Suraj S Zanwar, lien marked in favour of IDBI
- Equitable Mortgage of Residential Property situated at, "Shobha Carnation", Flat No. D1-2057, 5th floor, block no. 2, S. No. 19, Hiss No: 1/1A/1A/1, 16, Kondhwa, Pune-411048, owned by Shri Suraj Zanwar.
- Brand Assignment of all products of the Company by way signing deed of assignment/Deed of Hypothecation.
- Key Man insurance policy for Shri Suraj S Zanwar & Shri Pankaj Zanwar of Rs. 110 lakh each
- Pledge of 10% of the paid-up capital of Rs. 23.36 crore (i.e., 23,36,076 shares of Rs. 10/- each)

**Specific for CC.**

Second charge on pari-passu basis on all the immovable and movable fixed assets of the Company (present and future).

**Specific for TL.**

Second charge on pari-passu basis by way of hypothecation of entire current assets of the Company including stock and debtors (present and future).

**Personal Guarantees :**

Shri Suraj Shrinivas Zanwar  
 Smt. Kavita Suraj Zanwar  
 Shri Pankaj Shrinivas Zanwar  
 Smt. Sheetal Pankaj Zanwar  
 Smt. Shakuntala Zanwar  
 Shri Abhishek Bhandari (Guarantee to the extent of value of his collateral security Rs. 300 lakh)



**CIAN HEALTHCARE LIMITED**  
**MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,**  
**C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT**  
**PHURSUNGI, TAL. HAVELLDIST, PUNE-412308**  
**CIN: L24233PN2003PLC017563**

**NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS FOR THE PERIOD ENDED ON MARCH 31, 2024**

**Note 33: Other Disclosures**

**A) Change in Bank Accounts**

Due to mergers of banks Loan CC and Current accounts of have been moved to different banks

Below are the old and current corresponding account details for Long Term and Short Term Loans

OLD LOAN ACCOUNT DETAILS	CORROSPONDING NEW ACCOUNT DETAILS
Term Loan-Corp Bank-A/C No T1801160012	Term Loan - UBI A/C-8108
Term Loan-Dena Bank A/C-025954023861	Term Loan-BOB A/C-71010600000191
Term Loan - Corporation Bank A/C-0014	Term Loan - UBI A/C-7780
Term Loan - Corporation Bank A/C-40004	Term Loan - UBI A/C-8108
Term Loan - Dena Bank A/C - 3792	Term Loan - BOB A/C - 197
Term Loan - Vijaya Bank - 0045	Term Loan - BOB - 0183
Corp Bank ( C C ) - 044500401140001	UBI ( C C ) - 560101000005431
Dena Bank ( C C ) - 025913023845	BOB ( C C ) - 71010500000018

Due to mergers of banks Loans, Current accounts, FDs have been moved to different banks

Below are the old and current corresponding account details for Current account and FDs

OLD LOAN ACCOUNT DETAILS	CORROSPONDING NEW ACCOUNT DETAILS
Dena Bank - 025911023905 (Ca)	Bank of Baroda -71010200000287 (CA)
Vijaya Bank A/C - 510400481000007	Bank of Baroda -89740200000916 (CA)
Fixed Deposit - Vijaya Bank - 0478	Fixed Deposit - Bank Of Baroda - 1445
Fixed Deposit Dena Bank No 9997	Bank of Baroda -A/C NO.71010300003079
Fixed Deposit Dena Bank No 6266	Bank of Baroda A/C NO 71010300003080
Fixed Deposit Dena Bank No 8680	Bank of Baroda A/C NO 71010300001211
Fixed Deposit Dena Bank No 9995	Bank of Baroda A/C NO.71010300003078

**B)Delay (Default) in Payment of Interest, Principal and/ Both**

The company has delayed (defaulted) in the repayment of EMI/Interes/Principles on the loan amounts. As on 31.03.2024 below are the delayed (defaulted) payments.

Principal delay/default is included in Long term/Short Term Borrowings

BANK NAME	Nature of Loan	Delay/Default as on 31.03.2024
POONAWALLA FINANCE	Unsecured Loan	-
AXIS BANK	Unsecured Loan	-
BAJAJ FINANCE	Unsecured Loan	-
MAGMA FINCORP	Unsecured Loan	-
KOTAK MAHINDRA BANK	Unsecured Loan	212,230.00
DEUTSCHE BANK	Unsecured Loan	211,362.00
ECL FINANCE LTD.	Unsecured Loan	-
ECL FINANCE LTD.	Unsecured Loan	-
FULLERTON	Unsecured Loan	-
STANDARD CHARTERED	Unsecured Loan	-
YES BANK	Auto Loan	24,259.00
YES BANK	Auto Loan	32,648.00
YES BANK	Auto Loan	-
NEW GROWTH	Unsecured Loan	-
INDIA INFOLINE FINANCE LTD	Unsecured Loan	-
SIDBI	Term Loan	6,113,069.00
HDFC BANK	Unsecured Loan	106,792.00
BANK OF BAROA	Cash Credit/ Term Loan	9,193,667.00
UNION BANK	Cash Credit/ Term Loan	1,721,018.00
IDBI	Cash Credit/ Term Loan	-
<b>Total</b>		<b>17,615,045.00</b>



#VALUE!

Sr.No.	Description	Comments
1	<p><b>Details of Benami Property held:-</b> Where any proceedings have been initiated or pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and the rules made thereunder, the company shall disclose the following: -</p> <p>(a) Details of such property, including year of acquisition, (b) Amount thereof, (c) Details of Beneficiaries, (d) If property is in the books, then reference to the item in the Balance Sheet, (e) If property is not in the books, then the fact shall be stated with reasons, (f) Where there are proceedings against the company under this law as an abettor of the transaction or as the transferor then the details shall be provided, (g) Nature of proceedings, status of same and company's view on same.</p>	<p>We were neither involved and nor it has abetted in any kind of Benami Transactions.</p> <p>Hence this schedule is Not Applicable to the company.</p>
2	<p><b>Where the Company has borrowings from banks or financial institutions on the basis of security of current assets, it shall disclose the following:-</b> (a) whether quarterly returns or statements of current assets filed by the Company with banks or financial institutions are in agreement with the books of accounts. (b) if not, summary of reconciliation and reasons of material discrepancies, if any to be adequately disclosed.</p>	<p>Yes we have made proper compliances.</p>
3	<p><b>Willful Defaulter* :-</b> Where a company is a declared willful defaulter by any bank or financial Institution or other lender, following details shall be given: (a) Date of declaration as willful defaulter, (b) Details of defaults (amount and nature of defaults), * "willful defaulter" here means a person or an issuer who or which is categorized as a willful defaulter by any bank or financial institution (as defined under the Act) or consortium thereof, in accordance with the guidelines on willful defaulters issued by the Reserve Bank of India.</p>	<p>Not Applicable</p>
4	<p><b>Relationship with Struck off Companies:-</b> Where the company has any transactions with companies struck off under section 248 of the Companies Act, 2013 or section 560 of Companies Act, 1956, the Company shall disclose the following details: -</p> <p>a. Name of struck off Company b. Nature of transactions with struck-off Company c. Balance outstanding d. Relationship with e. the Struck off company, f. if any, to be disclosed g. Investments in securities h. Receivables i. Payables j. Shares held by stuck off company k. Other outstanding balances (to be specified)</p>	<p>Not Applicable</p>
5	<p><b>Registration of charges or satisfaction with Registrar of Companies:-</b> Where any charges or satisfaction yet to be registered with Registrar of Companies beyond the statutory period, details and reasons thereof shall be disclosed.</p>	<p>No charges pending for registration as on 31st March 2024</p>
6	<p><b>Compliance with number of layers of companies:-</b> Where the company has not complied with the number of layers prescribed under clause (87) of section 2 of the Act read with Companies (Restriction on number of Layers) Rules, 2017, the name and CIN of the companies beyond the specified layers and the relationship/extent of holding of the company in such downstream companies shall be disclosed.</p>	<p>Yes we have made proper compliances.</p>
7	<p><b>Following Ratios to be disclosed:-</b> (a) Current Ratio, (b) Debt-Equity Ratio, (c) Debt Service Coverage Ratio, (d) Return on Equity Ratio, (e) Inventory turnover ratio, (f) Trade Receivables turnover ratio, (g) Trade payables turnover ratio, (h) Net capital turnover ratio, (i) Net profit ratio, (j) Return on Capital employed, (k) Return on investment</p>	<p>Refer the Schedule of Ratio Analysis</p>
8	<p><b>Compliance with approved Scheme(s) of Arrangements:-</b> Where any Scheme of Arrangements has been approved by the Competent Authority in terms of sections 230 to 237 of the Companies Act, 2013, the Company shall disclose that the effect of such Scheme of Arrangements have been accounted for in the books of account of the Company 'in accordance with the Scheme' and 'in accordance with accounting standards' and deviation in this regard shall be explained.</p>	<p>Not Applicable</p>



9	<p><b>Utilisation of Borrowed Funds and Share Premium:-</b></p> <p><b>(A) Where company has advanced or loaned or invested funds (either borrowed funds or share premium or any other sources or kind of funds) to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding (whether recorded in writing or otherwise) that the Intermediary shall:-</b></p> <p>(i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or</p> <p>(ii) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries;</p> <p><b>The company shall disclose the following: -</b></p> <p>(I) date and amount of fund advanced or loaned or invested in Intermediaries with complete details of each Intermediary.</p> <p>(II) date and amount of fund further advanced or loaned or invested by such Intermediaries to other intermediaries or Ultimate Beneficiaries along with complete details of the ultimate beneficiaries.</p> <p>(III) date and amount of guarantee, security or the like provided to or on behalf of the Ultimate Beneficiaries</p> <p>(IV) declaration that relevant provisions of the Foreign Exchange Management Act, 1999 (42 of 1999) and Companies Act has been complied with for such transactions and the transactions are not violating the Prevention of Money-Laundering act, 2002 (15 of 2003).;</p>	Not Applicable
	<p><b>(B) Where a company has received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the company shall: -</b></p> <p>(i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or</p> <p>(ii) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries, the company shall <b>disclose the following: -</b></p> <p>(I) date and amount of fund received from Funding parties with complete details of each Funding party.</p> <p>(II) date and amount of fund further advanced or loaned or invested other Intermediaries or Ultimate Beneficiaries along with complete details of the other intermediaries' or ultimate beneficiaries.</p> <p>(III) date and amount of guarantee, security or the like provided to or on behalf of the Ultimate Beneficiaries</p> <p>(IV) declaration that relevant provisions of the Foreign Exchange Management Act, 1999 (42 of 1999) and Companies Act has been complied with for such transactions and the transactions are not violating the Prevention of Money-Laundering act, 2002 (15 of 2003).;</p>	Not Applicable
10	<p><b>Undisclosed Income:-</b></p> <p>The Company shall give details of any transaction not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961), unless there is immunity for disclosure under any scheme and also shall state whether the previously unrecorded income and related assets have been properly recorded in the books of account during the year.;</p>	Not Applicable
11	<p><b>Corporate Social Responsibility (CSR):-</b></p> <p>Where the company covered under section 135 of the Companies act, the following shall be disclosed with regard to CSR activities: -</p> <p>(a) amount required to be spent by the company during the year,</p> <p>(b) amount of expenditure incurred,</p> <p>(c) shortfall at the end of the year,</p> <p>(d) total of previous years' shortfall,</p> <p>(e) reason for shortfall,</p> <p>(f) nature of CSR activities,</p> <p>(g) details of related party transactions, e.g., contribution to a trust controlled by the company in relation to CSR expenditure as per relevant Accounting Standard,</p> <p>(h) where a provision is made with respect to a liability incurred by entering into a contractual obligation, the movements in the provision during the year should be shown separately.</p>	Not Applicable for FY 23-24
12	<p><b>Details of Crypto Currency or Virtual Currency:-</b></p> <p>Where the Company has traded or invested in Crypto currency or Virtual Currency during the financial year, the following shall be disclosed: -</p> <p>(a) profit or loss on transactions involving Crypto currency or Virtual Currency</p> <p>(b) amount of currency held as at the reporting date,</p> <p>(c) deposits or advances from any person for the purpose of trading or investing in Crypto Currency/ virtual currency.";</p>	Not Applicable

